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Dissecting the Mechanisms of Direct Activation for Proapoptotic BAK and BAX 
 
Abstract 
Pro-apoptotic BAK and BAX form toxic mitochondrial pores in response to cellular 
stress. Whereas BAX predominantly resides in the cytosol, BAK is constitutively localized to the 
outer mitochondrial membrane. Select BH3 domain helices directly activate BAX by engaging 
an α1/α6 trigger site. The inability to express full-length BAK has hampered full dissection of its 
activation mechanism. Here, I report the production of full-length, monomeric BAK by 
mutagenesis-based solubilization of its C-terminal α-helical surface. Recombinant BAK auto-
translocates to mitochondria, but only releases cytochrome c upon BH3 triggering.  A direct 
activation mechanism was explicitly demonstrated using a liposomal system that recapitulates 
BAK-mediated release upon addition of BH3 ligands alone.  Photoreactive BH3 helices mapped 
both triggering and auto- interactions to the canonical BH3-binding pocket of BAK, whereas the 
same ligands crosslinked to the α1/α6 site of BAX. Thus, BAK and BAX activation are initiated 
by direct BH3 interaction, but at distinct trigger sites. These structural and biochemical insights 
provide new opportunities for developing pro-apoptotic agents that activate the death pathway 
through direct but differential engagement of BAK and BAX.   
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Chapter 1 
 
 
 
Introduction 
 2 
Introduction to the BCL-2 family 
Introduction to apoptosis 
Apoptosis, or programmed cell death, is an essential biochemical pathway that allows 
organisms to control the function of cells and tissues in a concerted and defined manner. 
Apoptosis is critical during mammalian development, as well as for the maintenance of cellular 
homeostasis later in life. In accordance with the importance of this pathway, apoptosis is tightly 
regulated in order to properly balance proliferation and cell death. The disruption of either 
process can lead to disease: too little cell death leads to unregulated cell survival in diseases such 
as cancer and autoimmunity, while too much cell death can cause neurodegeneration, 
immunodeficiency, and infertility. Evasion of apoptosis is one of the hallmarks of cancer1. Two 
distinct but interconnected pathways are responsible for initiating apoptosis following signals of 
cellular stress. Extracellular signals stimulate the extrinsic apoptotic pathway, whereas 
intracellular stress initiates the intrinsic, or mitochondrial, pathway.  
The BCL-2 family-regulated intrinsic apoptotic pathway is initiated by intracellular 
processes of cellular stress, such as viral infection, DNA damage, growth-factor deprivation, or 
transcriptional cues2,3. This pathway is tightly controlled by the balance between the pro-death 
(proapoptotic) and pro-survival (antiapoptotic) members of the BCL-2 protein family and the 
protein-protein interactions among them. Apoptotic signals are ultimately relayed through this 
pathway, causing BCL-2-family-mediated destabilization of the outer mitochondrial membrane 
and release of cytochrome c and other apoptogenic factors from the mitochondrial 
intermembrane space4. This release triggers the formation of a protein complex known as the 
apoptosome, which consists of cytochrome c molecules, cytosolic protein APAF-1, and 
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procaspase-9 that is subsequently processed within the apoptosome complex into active caspase 
9, which is formed by cleavage5-7. 
The extrinsic pathway is triggered when the cell receives an external signal, such as 
tumor necrosis factor (TNF) family receptor trimerization upon binding to its cognate ligands at 
the cell surface8,9. These receptors contain an intracellular domain that is responsible for the 
recruitment and activation of caspase-8 (cysteine aspartyl protease) via its binding to the adaptor 
protein FADD (Fas-associated death domain) and for its subsequent cleavage into its active 
form. This results in the activation of the downstream effector caspases, caspase-3, -6 and -7 − 
an irreversible caspase cascade10. Alternatively, capase-8 can trigger the activation of BCL-2 
family member BID by cleaving it into an active truncated form, tBID, thus funneling the 
extrinsic death signal to the BCL-2 family-mediated mitochondrial apoptotic pathway11. 
Both apoptotic pathways converge at the activation of multiple caspases, which execute 
the dismantling and clearance of the cell destined to die. This caspase cascade is responsible for 
the physiologic features associated with apoptosis, including DNA condensation and plasma 
membrane blebbing. 
 
The BCL-2 protein family 
The founding member of the BCL-2 family was identified as a gene partner of 
immunoglobulin heavy chain translocation t(14;18) in follicular lymphoma, which leads to the 
pathologic upregulation of its gene product12,13. The gene was named Bcl-2, which represents the 
B-cell lymphoma 2 oncogene. It was later found that rather than promoting cellular proliferation, 
the BCL-2 protein inhibits cell death14, constituting the first of many examples in which aberrant 
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apoptosis contributes to a cancerous phenotype. Since then, more than 20 human BCL-2 family 
members have been discovered, all of which are involved in the precise control of apoptosis.  
All BCL-2 family proteins possess very high sequence and structural homology within 
several different evolutionarily conserved BCL-2 family homology regions (or domains), known 
as BH domains15. BCL-2 family protein sequences contain up to four of BH (BCL-2 homology) 
domains: BH1, BH2, BH3 and BH4, of which the most conserved and unifying is the BH3 
domain (Figure 1.1). The BH3 domain represents a conserved alpha helix that mediates protein-
protein interactions between BCL-2 family members. Interestingly, despite this very high 
homology and structural similarity, BCL-2 family proteins can have opposing functions and are 
thus functionally subdivided into three classes of proteins: antiapoptotic, multidomain 
proapoptotic, and BH3-only proteins (Figure 1.2). 
The primary function of pro-apoptotic BCL-2 family member proteins (such as BAK and 
BAX) is to execute mitochondrial induced apoptosis in response to stress stimuli16-18. Upon 
culmination of the apoptotic signal, activated BAX and BAK self-associate to form pores in the 
outer mitochondrial membrane19,20, resulting in the propagation and execution of the cell death 
cascade by releasing critical signaling factors, such as cytochrome c21,22 and Smac/Diablo23, 
which drive the apoptotic process. 
Antiapoptotic proteins counteract the function of pro-apoptotic members of the BCL-2 
family24,25. They inhibit BAK and BAX, by binding to and sequestering their BH3 domains – 
also called “death domains” – via a conserved BH3 binding groove26. This effective 
sequestration leads to a complete inhibition of apoptosis, both in homeostatic conditions and in 
disease 27. 
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Figure 1.1. The BCL-2 family of proteins. BCL-2 family proteins consist of multidomain 
proapoptotic, antiapoptotic, and BH3-only members. BCL-2 family proteins share a high degree 
of sequence similarity within the BH (BCL-2 homology) domains. BH3 domains mediate the 
protein-protein interactions within the BCL-2 family. 
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Figure 1.2. Mitochondrial apoptosis is regulated by the BCL-2 family protein interaction 
network. In response to stress stimuli, BH3-only proteins promote activation of BAX and BAK 
through direct and indirect mechanisms, leading to the transformation of monomeric BAX/BAK 
into oligomeric pores that pierce the mitochondrial outer membrane and release apoptogenic 
factors. BH3-only proteins can activate BAX/BAK through direct binding interactions and/or by 
targeting the BH3-binding pocket of antiapoptotic proteins, releasing BH3-only proteins and 
conformationally active forms of BAX/BAK sequestered in heterodimeric complex (left). 
Conversely, antiapoptotic proteins prevent BAX/BAK-mediated mitochondrial apoptosis by 
impounding the BH3 domains of BH3-only proteins and BAX/BAK in a surface groove,  
 7 
Figure 1.2 (Continued). 
 
effectively suppressing proapoptotic signaling (right). The life-or-death decision for the cell is 
ultimately dictated by the relative abundance and functional activity of pro- and antiapoptotic 
BCL-2 family proteins. 
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The third class of BCL-2 family members, BH3-only proteins, transmits the signals of 
cellular stress to the apoptotic machinery, and is also proapoptotic in nature. Diverse conditions, 
such as DNA damage28-30, growth factor deprivation31, and endoplasmic reticulum stress32, lead 
to the activation of BH3-only proteins. The exact mechanism of activation varies for different 
BH3-only proteins, ranging from transcriptional upregulation33, to phoshorylation34,35, protease 
cleavage11,36,37, and myirstoylation38. Once activated, BH3-only proteins “inhibit the inhibitors” 
by binding to the anti-apoptotic proteins and essentially neutralizing them, thus liberating BAX 
and BAK and allowing BAX/BAK-dependent apoptosis to be ensue39. Thus, the equilibrium 
between the antiapoptotic and BAK/BAX/BH3-only members of the BCL-2 family determines 
the cell’s susceptibility to apoptosis40. Specific interactions between all three classes of BCL-2 
proteins govern cell fate by tightly controlling the balance between the pro- and antiapoptotic 
stimuli. 
 
Structural aspects of the BCL-2 family 
The structures of multidomain BCL-2 proteins, i.e. antiapoptotic proteins and 
proapoptotic BAK and BAX, are strikingly similar, despite their opposing functions. All of these 
proteins have a globular structure with two core hydrophobic helices (α5 and α6) surrounded by 
several amphipathic α-helices15. The hydrophobic C-terminal α-helix is a transmembrane 
domain responsible for mitochondrial targeting. The standard approach of structural 
determination for these proteins has been through the truncation of the transmembrane region41-
43, a consequence of which is the omission of the C-terminal helix from all determined structures, 
with the only exception being an NMR structure of full-length BAX44. The majority of BH3-only 
proteins are intrinsically unstructured, except for BID (BH3-interacting domain death 
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agonist)45,46, which is so structurally similar to multidomain BCL-2 proteins that it was suspected 
to have an autonomous oligomerization capability47,48. 
Interactions between BCL-2 family proteins are mediated by the binding of the BH3 
domains of proapoptotic BAK, BAX or BH3-only proteins to the hydrophobic C-terminal 
binding pocket, or groove, on antiapoptotic proteins such as MCL-1, BCL-2, and BCL-XL. This 
interaction is stable, stoichiometric, and mutually neutralizing: once the BH3 binding pocket is 
occupied, no other allosteric site or modification on the antiapoptotic protein is available for an 
additional interaction. Accordingly, once their BH3 domains are bound and buried in the 
antiapoptotic hydrophobic binding groove, neither BAK/BAX, nor BH3-only proteins can exert 
their proapoptotic action. This binding interface is so ubiquitous for BCL-2 family 
heterodimerizations, that the term ‘canonical pocket’ was coined to describe this particular class 
of interactions. Structures of antipoptotic proteins complexed with peptides corresponding to the 
BH3 domains of other BCL-2 family members abound and all follow this described structural 
pattern26,43,49,50 (Figure 1.3, A). Despite homology within the canonical groove between anti-
apototic BCL-2 family members, the profile of BH3-only binding partners for each of these 
proteins is distinct. For example, MCL-1 binds NOXA and BAK BH3 helices, but does not 
interact with BAD BH3, while BCL-2 binds BAD, but not NOXA or BAK BH3. All 
antitapoptotic proteins readily bind BH3-only proteins BIM and PUMA, and potentially BID. 
Notably, BH3 domains of BAK and BAX are not exposed in the inactive 
conformations44,51, but rather represent an internal part of the globular fold. It is thus necessary 
for BAK and BAX to undergo a conformational change to become activated, or primed, in order 
to allow for hetero-, homodimerization and oligomerization. In fact, the result of this  
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Figure 1.3. Two sites of BH3 domain interaction on apoptotic proteins. The stable and 
inhibitory BIM BH3 interaction site on anti-apoptotic BCL-XL (A) and the dynamic and 
activating BIM BH3 interaction site on pro-apoptotic BAX (B) are geographically distinct.   (A) 
The bulk of the BIM BH3 binding interface with BCL-XL comprises extensive contacts between 
the hydrophobic face of the a-helix and the hydrophobic cleft formed at the protein surface by a  
 11 
Figure 1.3 (Continued). 
 
confluence of residues from BCL-XL  a-helices 2, 4, 5, 7, and 8.   (B) In the inactive, monomeric 
form of BAX, the canonical BH3 binding pocket is occupied by BAX’s C-terminal a9 helix. By 
contrast, the surface groove of the BAX activation site, located on the opposite side of the 
protein at the confluence of BAX a-helices 1 and 6, is accessible for BH3 triggering. 
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conformational change – the N-terminal exposure of BAK and BAX – is an early marker of 
apoptosis, and as such is widely used in studies characterizing the onset of cell death52-54. 
Whether the canonical hydrophobic binding pocket also exists on BAK and BAX is still 
uncertain. The NMR structure of BAX is the only BCL-2 family protein structure that contains 
the full-length C-terminal domain, and strikingly, this very domain occupies the canonical 
pocket, thus occluding and rendering it unavailable for interactions, at least in the inactive state 
of the protein. The full-length structure is not available for BAK, and interestingly, both C-
terminally truncated structures of BAK reveal a severely collapsed canonical pocket51,55. With 
the overall fold similar to that of BAX, the canonical pocket in BAK is dramatically occluded. 
This either suggests that the C-terminal helix may play a role in shaping the canonical pocket 
binding surface, enforcing  a structural difference compared to antiapoptotic proteins structures, 
or it could simply represent a difference in its native fold from that of BAX, which is likely due 
to the membrane localization of BAK and, presumably, its membrane-embedded C-terminus. 
 
BCL-2 proteins in health and disease 
The critical role of BCL-2 family proteins in apoptosis translates into dependency on 
BCL-2 proteins during normal tissue homeostasis, with deregulation contributing to disease.  
Mice deficient in Bcl-2 or Bcl-XL are embryonic lethal56,57. This highlights the importance 
of maintaining cellular survival by counteracting apoptosis at the developmental stage. Some 
cells, however, have to die during embryonic development to allow tissue remodeling and organ 
formation. Accordingly, maintaining the ability to apoptose is crucial and the majority of mice 
that lack both BAK and BAX (Bax-/-Bak-/-) die during embryonic development due to severe 
neurological defects58. Mice with deletions of either only BAK or only BAX, however, have 
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relatively few defects58,59, providing insight into some degree of redundancy in the functions of 
BAK and BAX. 
Deletion of single BH3-only protein genes results in few developmental defects in mice 
(with the exception of BIM60), probably due to an even greater redundancy within this subgroup 
of the family. When several of the BH3-only proteins are concomitantly deleted, a defective 
phenotype becomes much more apparent: the triply negative Bim Bid Puma KO mice 
recapitulate many of the features of Bax-/-Bak-/- mice61. Collectively, these studies highlight a 
critical role for BCL-2 family during development, as well as the complex nature of unique and 
redundant functions within the family.  
Inhibition of apoptosis is a hallmark of cancer1. The discovery of the BCL-2 protein at 
the t(14;18) translocation proved that it was causally linked with follicular B-cell lymphoma12,13. 
Since then, many more examples of antiapoptotic upregulation leading to cancer have been 
observed, including chronic lymphocytic leukaemias62, breast carcinomas63, non-Hodgkin’s 
lymphoma64 and glioblastomas65. Hijacking the apoptotic machinery seems to be an effective 
means for malignant cells to promote cell survival. High levels of antiapoptotic proteins are often 
prognostic of disease aggressiveness and diminished therapeutic response66.  
Proapoptotic BAK and BAX deletions in cancers are relatively rare, likely due to the fact 
that both copies of both genes would have to be deleted for an observable advantage – due to 
their functional redundancy and significant expression of both BAK and BAX in most tissues. 
Still, low levels of BAK and BAX, as well as a low ratio of proapoptotic to antiapoptotic 
proteins, have been linked to poor prognosis and chemotherapeutic resistance66-68.  Based on 
these findings, the determination of the ratio of pro- to antiapoptotic BCL-2 proteins by ‘BH3 
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profiling’ has been proposed as a clinical predictive tool to estimate potential chemotherapeutic 
reponses69-71. 
 
Pro-apoptotic BCL-2 family members BAK and BAX 
BAK is a pro-apoptotic BCL-2 family member that resides in the mitochondrial outer 
membrane as a quiescent monomer until stimulated by cellular stress to undergo conformational 
activation and oligomerization19,20. First discovered in 199517,18,72, BAK was found to share 
functional homology with BAX, each containing an essential BH3 domain required for 
oligomerization-based killing activity73. The solution structure of the BAK BH3 domain 
complexed to a surface groove on anti-apoptotic BCL-XL defined a protein interaction paradigm 
that contributes to BCL-2 family regulation of mitochondrial apoptosis49. Indeed, anti-apoptotic 
suppression of BAK and BAX through sequestration of BH3 helices is such an effective means 
of blocking apoptosis that cancer cells hijack and amplify this natural regulatory mechanism to 
enforce pathologic cell survival. 
In the inactive state, BAX is a soluble, cytosolic, and monomeric protein74,75 whose 
hydrophobic surfaces are buried within its core, including its C-terminal membrane insertion 
helix that is entrapped in the canonical surface groove44. In order to perform its function, BAX 
must be translocated from the cytosol, where it resides under homeostatic conditions, to the 
mitochondria. In contrast, monomeric BAK is a membrane-resident protein39 whose C-terminus 
is presumably dislodged from the canonical binding groove and inserted into the outer 
mitochondrial membrane, potentially rendering BAK more vulnerable to activation in the 
absence of additional “security” mechanisms. Although a matter of ongoing debate, the 
homeostatic suppression of BAK may involve structural stabilization of the inactive monomer as 
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a result of conformationally restricted access to the canonical binding groove51,55, and/or 
constitutive interactions with anti-apoptotic proteins76, voltage-dependent anion channel 277, 
and/or perhaps other unknown proteins. 
 
Mechanism of BAK and BAX activation 
Although BAK and BAX are an essential gateway to apoptosis78, and when deleted give 
rise to severe developmental defects58, a host of questions persist regarding the physiologic 
mechanisms that govern their inhibition, activation, and self-association. Owing to a wealth of 
structural and biochemical studies that elucidated the mechanistic basis for anti-apoptotic 
suppression of the conformationally-activated, BH3-exposed forms of BAX and BAK25,43,49,76,79, 
this aspect of BAX/BAK regulation is widely accepted and has formed the basis for major efforts 
to pharmacologically disrupt such interactions to reactivate apoptosis in human cancer80-82. 
However, the mechanisms by which BAK and BAX are activated have been the focus of much 
debate. Two models have been proposed: a direct activation model and an indirect activation 
model83,84. The indirect activation model proposes that BAK and BAX homeostatically exist in 
primed form and as soon as antiapoptotic inhibition is relieved, BAX and BAK proceed to form 
oligomers39,76. However, this model does not explain the stimulus responsible for the initial BAX 
and BAK activation event, and fails to account for the fact that only a small fraction of BAX and 
BAK is bound to antiapoptotic proteins in healthy, non-apoptotic cells85. 
 The direct activation model posits that in addition to inhibiting the anti-apoptotic 
proteins, a direct triggering interaction is necessary to activate BAK and BAX86, most likely by 
the BH3-only proteins.The hypothesis that BH3-only proteins could activate multidomain pro-
apoptotics through direct and transient engagement dates back to the very discovery of the BH3-
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only protein BID, based on its interaction with BCL-2 and BAX87. However, likely due to the 
transient nature of the proposed direct interaction, binding of activator BH3-only proteins to 
BAX and BAK was controversial and difficult to detect. Subsequent studies documented the 
capacity of select BH3-only proteins and BH3 peptides to induce recombinant BAX-mediated 
pore formation in liposomal and mitochondrial systems88,89, with hydrocarbon-stapled peptide 
helices corresponding to the BID and BIM BH3 domains employed to explicitly detect and 
quantitate direct binding interactions with BAX90.  Structural and biochemical analyses of the 
interaction between full-length recombinant BAX and a stapled BIM BH3 helix revealed a non-
canonical BH3 interaction site at the confluence of BAX α-helices 1 and 6, a trigger site for 
BH3-mediated direct BAX activation (Figure 1.3, B)91.  Upon engagement by a triggering BH3 
ligand, BAX undergoes a major conformational change that includes allosteric release of its C-
terminal helix for mitochondrial translocation and exposure of its BH3 domain, which both 
propagates BAX activation and induces functional oligomerization within the mitochondrial 
outer membrane92.  
While there is a substantial amount of research devoted to BAX91,93, little is known about 
the direct activation mechanism for BAK, an equally important mediator of the cell death 
process. BAK was shown to co-immunoprecipitate with the activated form of BID, tBID, in 
whole cell lysates19, but the overall evidence for such direct interactions of BAK in cells and in 
vivo is very limited. In contrast to BAX, full-length BAK has been refractory to protein 
expression and purification76, precluding the corresponding structural and biochemical studies to 
dissect its interactions and activation mechanisms using fully intact recombinant protein.  
Instead, truncated forms of BAK have been generated and employed in a series of studies that 
documented (1) dimeric structures of BAK truncates 23-185 and 16-18651,55, (2) binding of select 
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BH3 domains to the exposed canonical pocket of BAKΔC94 and N- and C-terminal calpain-
cleaved BAK (cBAK)51, (3) auto-active and ligand-stimulated pore-forming functionality of an 
artificially membrane-tethered form of BAKΔC95, and (4) BH3 ligand-induced activation of 
BAK truncates in liposomal and mitochondrial release assays94,96,97. The application of select 
BH3 peptides to native BAK-containing mouse liver mitochondria98 and of IVTT (in vitro 
transcribed and translated) BH3-only proteins to mitochondria isolated from wild-type and 
mutant BAK-reconstituted DKO MEFs may also implicate a direct activation mechanism for 
BAK-mediated mitochondrial apoptosis99,100.  
Despite significant efforts to define the mechanism of BAK and BAX oligomerization, 
how these proteins self-associate to form pores remains elusive. An insertional cysteine 
mutagenesis and disulfide crosslinking approach implicated the involvement of two binding 
interfaces, BAK BH3 domain in canonical groove and α6/α6 interactions, in propelling BAK 
poration via an oligomerization of dimers mechanism101,102, a model also supported by EPR 
(electron paramegnetic resonance) analysis95. More recently, a similar mode of oligomerization 
was proposed for BAX103. In the absence of definitive structural support for this model, it 
remains unknown just how an oligomer of dimers would integrate into a membrane bilayer using 
its once buried hydrophobic surfaces. Crystallization of α2-α5 of BAX, a dramatically truncated 
BAX form, also hinted at the possibility of dimeric oligomer structure and provided some insight 
into the possible structure of the dimeric unit, yet it is still unclear how the pore is assembled in 
the presence of a lipidic bilayer104. Interestingly, cryo-EM studies of BAX-permeabilized 
liposomes documented that BAX oligomeric pores are non-uniform in nature and grow in size 
over time91, presumably as a chain reaction with each oligomeric complex recruiting more and 
more BAX molecules to participate and eventually lead to strikingly large openings in 
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membranes. These studies are corroborated by in vivo studies of the size of BAK and BAX 
oligomers, with estimates ranging from 25 to 1340 kDa as detected by chemical 
crosslinking105,106 and size-exclusion fractionation107. So far, the maximal BAX or BAK pore 
size has not been determined, and it is in fact unclear whether there are any constraints on the 
growth of the oligomeric pore or if there are other protein subcomponents. 
Lipids play an important role in BAK and BAX oligomerizaion. Mitochondrial outer 
membrane permeabilization requires a tight cooperation between BAK/BAX, their activators, 
and the lipidic membrane85. Not only is the hydrophobic lipid bilayer the medium in which BAK 
and BAX oligomerization takes place93, certain lipids can actively contribute to BAX and BAK 
conformational change and pore-forming activities. Some lipids have been shown to aid in the 
recruitment of BAX to the mitochondrial membrane, with the notable example of cardiolipin108-
110. Lipids can also be components of the lipidic/proteinaceous apoptotic pore89,111,112. Recently, 
it was shown that sphingolipid metabolism cooperates with BAK and BAX activation, with 
specific byproducts necessary to sensitize mitochondria to permeabilization by BAX and BAK. 
Interestingly, sphingosine-1-phosphate was found to specifically promote BAK pore-forming 
activity, whereas another sphingolipid metabolite, hexadecenal, plays a role in BAX function113. 
Taken together, these studies highlight the importance of studying BAK and BAX 
activity in the lipidic membrane context, and also reveal the complexity of factors involved in 
BAK and BAX regulation and activation. 
 
Challenges of studying BCL-2 family members 
Some of the intrinsic properties of BCL-2 family proteins make them difficult to study, 
both in an in vitro and in vivo context. In vivo, genetic knockout studies have proven to be 
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extremely useful to elucidate the importance of several BCL-2 family members, such as BCL-2, 
BCL-XL, MCL-1, BAK/BAX, and BIM56,57,114. Genetic studies also provided insight into a 
mechanistic understanding of apoptosis61,76, however the functional redundancy among family 
members renders interpretation of such experiments difficult. 
Co-immunoprecipitation has been employed to study the interactions among BCL-2 
family members, but this approach may not be as suitable for detecting transient binding 
interactions90. Moreover, some detergents that are commonly used for studies in cellular lysates, 
such as Triton X-100, have been shown to artificially activate BAK and BAX8, which imposes 
great restrictions on interpretation of data obtained by these techniques. 
Several other features of BCL-2 family members complicated discerning between the 
proposed direct vs. indirect activation mechanisms of mitochondrial permeabilization. Some 
BCL-2 family proteins, such as BAK, are hydrophobic and localized to membranes; other 
members of the BCL-2 family, such as BAX, shuttle from the cytosol to the mitochondrial 
membrane, complicating biochemical expression and purification, structural determination, and 
even mass-spectrometry analysis.  
Conformational alterations associated with BCL-2 family function are also difficult to 
pinpoint due to the transient nature of these changes. The N-terminal exposure in BAK and BAX 
detected by conformation-specific antibodies52 and protease susceptibility115 dramatically change 
over the course of BAX and BAK activation. The conformational change associated with BAK 
and BAX membrane embedding that is necessary to promote the oligomeric structure is 
reminiscent of near full protein unfolding, according to some models116. Moreover, even when 
oligomerized, BAK and BAX are elusive as it is impossible to pinpoint the precise species of the 
oligomer66, due to the increase in pore size over time. Clearly, this family represents a unique 
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challenge for structural determination, yet its central role in apoptosis regulation has marshaled 
tremendous research attention.  
With the lack of definitive structural knowledge, biochemical techniques have been 
employed to gain indirect insight into the mechanistic structural biology of BAX and BAK. 
Chemical crosslinking has shown some promise for answering several pressing questions about 
BAK and BAX activation101-103. However, routinely employed disulfide crosslinking may be 
biased because of the selective installation of non-native cysteine residues into the protein 
sequence, which introduces uncertainly in interpreting these data. The fairly low temporal 
resolution of crosslinking techniques is another limiting factor117. 
Given the shortcomings of disulfide crosslinking approaches, alternative biochemical 
experiments have allowed more definitive dissection of BAX/BAK  interactions93. Indeed, 
generating full-length forms of BCL-2 family proteins is crucial for definitive elucidation of their 
physiologic mechanisms. 
 
Hydrophobic proteins: associated challenges 
Most BCL-2 family proteins are associated with intracellular membranes at least at some 
point in the signaling cascade. Indeed,  properties intrinsic to all membrane proteins significantly 
hinder their mechanistic and biochemical dissection in vitro. Structural determination and 
biochemical analysis of membrane proteins has generally lagged in comparison to their cytosolic 
counterparts. A striking illustration of this is the fact that only 2% of the structures deposited in 
the protein data bank are membrane proteins, whereas membrane proteins constitute 30% of the 
mammalian proteome118. In addition, membrane proteins account for 60% of all drug targets119. 
This disparity often derives  from difficulties in expressing membrane proteins, which are 
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usually expressed at low levels in cells. Despite the introduction of many new expression 
systems in recent years, low yields, often due to toxicity, is still a recurring problem with 
recombinant expression and biochemical purification of membrane proteins.  
As membrane proteins are unstable in aqueous solution, detergents often have to be used 
at concentrations higher than their CMC (critical micelle concentration). Unfortunately, BCL-2 
family proteins are extremely sensitive to these environments85, which greatly limits the options 
to unfold and refold them in vitro during isolation. In addition to expression and purification 
issues, X-ray crystallography, NMR protein spectroscopy and even mass spectrometry have 
limitations for membrane protein analysis. These challenges highlight the need for new tools and 
techniques to gain a better understanding of how membrane proteins, and in particular, BCL-2 
family members, function in their native setting. 
 
Summary 
The BCL-2 family plays a crucial role in apoptosis. It consists of three sub-classes: 
multidomain proapoptotic, antiapoptotic, and BH3-only proteins. Proapoptotic proteins BAK and 
BAX, when not inhibited by antiapoptotic BCL-2 family proteins, oligomerize in the outer 
mitochondrial membrane to form toxic pores that release apoptogenic factors from the 
mitochondrial intermembrane space, triggering the caspase cascade and dismantling the cell. 
Whether BAK and BAX need to be activated by a specific trigger to oligomerize has been the 
focus of intense debate. Recent studies with recombinant full-length BAX revealed the crucial 
dependency of its activation on the interaction with BH3-only proteins. The interaction site has 
been structurally defined at the confluence of α-helices 1 and 6 at the N-terminal face of the 
protein, which lies on the opposite side of protein from the   canonical BH3 groove of BAX. 
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Thus far, recombinant full-length BAK had been refractory to expression and isolation in a pure 
monomeric form, precluding definitive biochemical studies of its activation behavior. 
 
Stapled peptides as research tools and prototype therapeutics 
Alpha-helices mediate protein-protein interactions 
The spatial structure of proteins and their binding compatibilities play a crucial role in 
mediating protein-protein interactions. Specific substructures, such as α-helices, β-sheets, β-
turns, and coiled coils, all participate in determining the binding affinity between two proteins. 
As such, protein-protein interaction surfaces tend to be large in their surface area and encompass 
many amino acid residues. While the resultant complexity of such large surfaces creates a 
versatile medium for distinguishing between homologous targets, it simultaneously renders 
prediction of the important specificity determinants of the interface quite difficult. Studying and 
recapitulating these protein-protein interactions in vitro and in vivo can therefore be challenging. 
Generating chemical inhibitors of such interactions has also proven to be difficult due to the 
absence of small and well-circumscribed binding pockets. 
The peptide α-helix represent the single largest class of protein secondary structures120,121 
and mediates an abundance of  of physiologic protein interactions. α-Helices as protein 
subcomponents tend to be rather small and span 2 to 3 helical turns122,123. With this in mind, it is 
theoretically conceivable to design an α-helix as a protein mimetic, serving both as a discovery 
tool and a prototype therapeutic. However, once excised from the protein sequence and overall 
tertiary fold, secondary structures rarely preserve their conformation and shape. In the case of α-
helices, unstabilized peptides lose their helical shape, becoming essentially a mixture of different 
conformers, and as such, fail to mediate protein interaction  as effectively as when in the context 
 23 
of the original full-length protein124. Additionally, proteolytic instability of unstructured 
peptides, as well as their cellular impermeability, makes them unsuitable for mechanistic 
dissection in cells and in vivo. 
The ability to preserve the helical shape of an isolated peptide would address many of the 
shortcomings of peptides. By restoring the peptide’s original shape, the original interaction 
specificities may be restored125, and as most proteolytic enzymes rely on  extended peptide 
chains for cleavage, α-helical conformation could also remedy the proteolytic instability of short 
peptides126. Some stabilized helices have also been shown to be effectively taken up by cells, 
most likely due to the reduced exposure of the polar amide backbone as a result of helical 
stabilization124. 
 
Strategies for stabilization of α-helical peptide conformation 
Several approaches have been successful used to stabilize the α-helical structure of short 
peptides. Three general strategies exist: (1) stabilization of the native-alpha-helical sequence by 
side-chain crosslinking or hydrogen bond surrogates127; (2) creating ‘foldamers’, which are 
peptide analogs employing β- or γ-amino acids and are capable of adopting conformations 
resembling an alpha helix128; (3) helical surface mimetics that are chemically unrelated to the 
original peptidic backbone but are designed to mimic the pattern of positioning of the side 
functional groups on a peptide helix129. The latter may include conformationally restricted 
scaffolds (such as rigid terphenyls). Out of this list of different approaches, only the first strategy 
involves the use of α-amino acids as building blocks and produces native α-helical shapes, thus 
most fully recapitulating the structural pattern of an α-helical interaction domain. 
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The α-helix contains 3.6 residues per turn, which positions i, i+4, i+7, i+11 residues on 
the same side along a folded helix. It is thus conceivable to stabilize the α-helical fold by 
crosslinking the residues between i and i+4 or i and i+7 positions. Lactam130, disulfide131, and 
metal chelating bonds132 have all been used in this capacity to create α-helicity in a given peptide 
sequence. Hydrocarbon stapling derived from olefinic metathesis reaction of the side functional 
groups of the peptide has also been employed with great success (Figure 1.4). Compared to 
lactam and disulfide bonds that are susceptible to protease digestion or a reducing intracellular 
environment, respectively, all-hydrocarbon stapling provides resistance to proteolysis80. 
Depending on a combination of factors, including hydrophobicity, amphipathicity, and overall 
charge, all-hydrocarbon stapled peptides can also demonstrate increased propensity for cellular 
uptake. 
In addition, several studies reported using hydrogen bond surrogates as a method to 
stabilize or nucleate  α-helicity. In this approach, a covalent bond is substituted for a hydrogen 
bond between a carbonyl group at i and an N-H group at i+4 residues in the neighboring helical 
turns. A hydrazone bond133 or a carbon-carbon double bond obtained by olefinic metathesis were 
both proposed and used successfully to recapitulate the native α-helical shape, although only 
when applied to short (7-15 residues) peptides134,135. 
Several studies examined the influence of linker rigidity on helix stability. A rigid, 
aromatic staple that spanned i, i+11 has provided much greater stability than a flexible linker of 
comparable length136. Analysis of various flexible and rigid linkers, as well as their positioning 
along the peptide helix and the distance between the crosslinked residues, confirmed that the 
rigidity of the linkers can lead to improved α-helical stabilization137. Another interesting 
approach involved the application of “click” chemistry to generate a triazole-containing staple by  
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Figure 1.4. All-hydrocarbon peptide stapling. Insertion of non-natural amino acids bearing 
olefin tethers at i, i+4 positions within the peptide sequence followed by ruthenium-catalyzed 
olefin metathesis generates stabilized α-helical domains. 
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the use of the Huisgen 1,3-dipolar cycloaddition reaction138. High efficiency and mild conditions 
contributed to the attractiveness of this approach. Because this crosslink is generated from 
asymmetrical building blocks (side chains in the peptide sequence), it allowed for easier 
generation of a doubly stapled BCL9 peptide with markedly increased  helicity, stability, and 
binding affinity towards β-catenin, although cell uptake was not achieved. 
 
Hydrocarbon stapling 
All-hydrocarbon stapling of peptides is perhaps the best characterized approach for 
stabilizing alpha-helical structures. Initial attempts to generate an all-hydrocarbon stapled 
peptide were made by Grubbs and co-workers who employed O-allyl modified serine derivatives 
in the peptide sequence. Ring-closing metathesis generated a covalent linkage spanning one 
helical turn139. Unexpectedly, these peptides did not display increased helicity. In another study, 
Schafmeister et al. carefully investigated the stereochemistry and linker length to successfully 
obtain hydrocarbon-bridged peptides with increased helical stabilization140. The key advance was 
the use of α,α-disubstituted amino acids for the crosslinkable side chains, which provided 
additional methyl groups at the α-carbon position and limited peptide backbone rotation by 
restricting the ϕ and ψ angles, and therefore promoted α-helicity. 
Interestingly, while some configurations provided significant helical stabilization, others 
destabilized the helix. Even small changes in crosslinked ring size or configuration lead to 
dramatic changes in outcome: as one of several examples, the 31-membered macrocycle – 
corresponding to R, S crosslinking at i, i+7 positions with 9 carbons in the metathesized 
crosslink – formed successfully, while shortening the crosslink by one carbon under the same 
exact conditions completely abrogated the macrocycle formation. This suggested that 
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‘templating’ of the ring-closing metathesis reaction was achieved by short-lived, dynamic helix 
induction. Schafmeister et al. found that optimal crosslink length led to effective α-helical 
stabilization, whereas crosslinks that were too short or too long led to suboptimal or even 
decreased α-helicity by hindering the formation of a proper α-helix by the former, or not 
providing enough restraint and stabilization by the latter. Once the intended helical stabilization 
was achieved, the binding affinity of the peptide to its target was greatly increased80,141-143 by 
alleviating the entropic cost of binding144. 
Select all-hydrocarbon stapled peptides penetrate the cells effectively, as assessed by 
flow cytometry, confocal microscopy and intracellular fluorescence detection,80,141,143 and are 
thus capable of targeting intracellular protein targets. Stapled peptide uptake was inhibited when 
the active (energy-dependent) forms of cellular uptake were blocked. However, stapled peptides 
did not co-localize with transferrin-labeled endosomes80 and instead tracked with dextrans, 
consistent with a pincytotic mechanism of cellular uptake.   
As cleavage by proteases is a key pathway for peptide elimination in biological systems, 
examining the protease susceptibility of stabilized peptides is an important measure of 
translational potential. All-hydrocarbon stapled peptides are significantly resistant to protease 
digestion compared to non-crosslinked analogs80,140,143,145. Overall structural reinforcement 
minimizes the presence of unfolded conformations of the peptide and thus leads to decreased 
susceptibility to proteolytic cleavage at any residue along the peptide sequence. Additionally, 
proteomic studies showed that the sites directly adjacent to the staple are virtually spared of 
proteolytic degradation, most likely due to the complete inability to unfold at the covalently 
restrained region. Importantly, the increased proteolytic stability in vitro was predictive of 
enhanced performance of stapled peptides in vivo80,145, at least in part due to the optimized 
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pharmacokinetic properties and sustained plasma concentration. In the case of the HIV derived 
T649v peptide, incorporation of two hydrocarbon staples led to the development of a double-
stapled construct that even exhibited oral bioavailability in mice, which contrasts to the twice 
daily subcutaneous mode of administration for the FDA-approved  HIV fusion inhibitor peptide 
Enfuvirtide145. 
These diverse examples confirm that chemical stabilization of α-helical peptide 
conformation is a viable strategy to confer the desired shape to an otherwise unstructured 
peptide, and clearly indicate the benefits of the use of a proteolytically-resistant, cell-permeable 
stapled peptide, afforded by installing an all-hydrocarbon crosslink. 
 
Stapled peptides as prototype therapeutics 
As α-helices are frequent motifs in protein-protein interactions, stabilized peptides hold 
great promise to selectively disrupt or, conversely, stabilize protein-protein interactions and thus 
serve as prototype therapeutics for the manipulation of physiologic or aberrant pathways in 
disease.  Because protein-protein interactions tend to employ large interaction surfaces, 
frequently lacking defined deep binding pockets146 required for small molecule targeting, they 
represent a formidable pharmacologic challenge. When properly leveraged, the distinctive 
characteristics of stabilized peptides offer a unique opportunity and an extremely attractive niche 
for therapeutic design. One major limitation for peptide therapeutics is their diminished efficacy 
in vivo, mostly due to their proteolytic instability, cellular impermeability and compromised 
structural fold when taken out of the three-dimensional protein context. As peptide stapling has 
been shown to redress these liabilities, stapled peptides are being developed as promising next 
generation peptide therapeutics for targets that have been refractory to small molecule inhibition. 
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Several successful examples of the development and application of stabilized peptides as 
potential therapeutics are discussed below. 
Among several oncologic pathways that drive cancer, evasion of BCL-2-family-mediated 
apoptosis has emerged as a significant barrier to treatment. Sequestration of the BH3 domains of 
BAK, BAX and BH3-only proteins by the canonical pockets of overexpressed antiapoptotic 
BCL-2 proteins represents the key mechanism by which apoptosis is blocked in human cancers. 
The critical BH3 interaction domain is a conserved α-helix and is thus an attractive substrate for 
the development of pharmacologic agents to overcome antiapoptotic inhibition. Indeed, stapled 
peptides modeled after the BH3 domains of BH3-only proteins BIM and BID (proapoptotic 
activators) have been shown to directly bind to antiapoptotic proteins such as BCL-XL, BCL-2 
and BFL-1 with low nanomolar affinity141, and have demonstrated the capacity to induce 
apoptosis at low micromolar concentrations in leukemia cells. Moreover, both BID and BIM 
stapled peptides, as single agents or in combination with ABT-263, halted tumor growth in 
mouse models of aggressive leukemia and often produced a dramatic decrease in tumor burden, 
while sparing normal tissues. 
Transcription factors are another class of proteins that are notoriously difficult to target. 
With the exception of nuclear hormone receptors that contain binding pockets for their respective 
ligands, transcription factors usually lack a defined hydrophobic pocket, and instead possess 
extended protein-protein interfaces. Thus far, potent and specific small molecule inhibitors are 
not available, despite the overwhelming importance of master transcription factors, such as myc 
and ras, in development and disease. Two examples of stapled peptides provided proof-of-
concept that transcription factor targeting can be successful both in vitro and in vivo. NOTCH 
signaling is directly implicated in several diseases, most notably NOTCH-dependent 
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cancers147,148 that are causally linked to NOTCH-activating mutations. An opportunity for direct 
inhibition of the NOTCH transcription factor complex emerged from the discovery of the 
dominant negative fragment of mastermind (MAML1) protein that interferes with the NOTCH 
transactivation complex149,150. Specifically, a stapled peptide modeled after the 16-amino acid 
stretch of the dominant negative MAML1 sequence was capable of disrupting the transactivation 
complex of NOTCH intracellular domain (ICN) with its DNA transcription factor partner CSL 
by competitively displacing MAML1151, whereas a point mutant construct served as a specificity 
control. After binding, the active stapled peptide, but not the control peptide, repressed NOTCH 
target gene expression and thus halted the proliferation of NOTCH-sensitive acute T-
lymphoblastic leukemia (T-ALL) both in culture and in vivo.  
Another elegant example of transcription factor targeting is inhibition of Wnt signaling 
by the stapled peptide derived from the sequence of the Wnt downstream transcriptional factor 
coactivator, BCL9152. This peptide was designed to competitively inhibit formation of the 
BCL9/β-catenin activating complex, and was shown to reduce the proliferation of colorectal 
cancer and multiple myeloma cell lines. In mouse models of Wnt-driven cancer, the stapled 
peptide, in a sequence-dependent manner, suppressed tumor growth, angiogenesis, and 
metastasis with little observed toxicity to normal tissues. 
Several other studies have been successful in applying the stapled peptide approach to 
notoriously difficult targets. A stapled peptide derived from a helical region of p53 was shown to 
competitively bind to the p53 inactivators MDM2 and MDMX, resulting in a surge in native p53 
protein and reactivation of the death pathway143. This p53-derived stapled peptide inhibited 
tumor cell proliferation as a single agent, and was shown to synergize with nutlin-3, an MDM2 
inhibitor, in vitro and in a mouse model of MDMX-driven choriocarcinoma. Additional 
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examples include the use of stapled peptides to inhibit the proliferation in HIV, where mimetics 
of HIV gp41145 or the C-terminal domain of HIV-1 capsid153,154 led to blockade of viral fusion or 
viral assembly, respectively. 
 
Stapled peptides as research tools for structural elucidation 
As biological discovery tools, stapled peptides have been especially fruitful in the 
dissection of BCL-2 family protein functions and mechanisms. One of the important 
advancements relates to dissecting the BAX activation mechanism. Whether BAX 
oligomerization and mitochondrial poration are active processes that require direct triggering by 
another protein partner, or whether oligomerization is the default BAX state, executed once 
antiapoptotic inhibition is relieved, has been the subject of active discourse in the cell death field. 
The debate overdirect vs. indirect models of BAX activation was successfully addressed by use 
of stapled peptides corresponding to the proposed BAX activators – BH3-only proteins – 
allowing for functional and structural studies of direct BAX binding. By stapling the BH3 
domain of BID, Walensky et al. showed BID SAHB (stabilized alpha-helix of BCL-2 domain), 
directly interacted with BAX, which led to its activation, pore formation in a liposomal assay, 
and cytochrome c release from mitochondria, in BAX- and SAHB-dependent fashion90. 
Gavathiotis et al. subsequently showed that the stapled peptide corresponding to the BH3 domain 
of another BH3-only protein, BIM (BIM SAHB), interacted with BAX at a novel trigger site91 on 
the opposite side of the protein from the canonical hydrophobic pocket, that correspondsto the 
location of the antiapoptotic binding groove. This structural information was obtained by protein 
NMR spectroscopy using chemically modified BIM SAHBs to determine the orientation of the 
BH3 domain. BIM SAHBs modified with a paramagnetic label, TEMPO, at N- or C-termini, 
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resulted in peak intensity changes in select subgroups of residues of BAX, providing key 
distance information that enabled successful docking of the peptide at the novel binding site 
(PDB ID 2K7W). Indeed, the versatility of SAHBs, in terms of their potential to be readily 
modified chemically to suit a variety of needs, provides fresh opportunities to dissect the 
structural and functional features of protein interactions. 
Interestingly, the canonical pocket in BAX in its monomeric state is occupied with its 
own C-terminal hydrophobic α-helix, thus precluding BH3 domain binding to that region. 
However, as soon as BH3 binding occurs at the recently discovered allosteric trigger site, BAX 
undergoes a major conformational change that includes the displacement of the loop located 
between helices 1 and 2, exposure of the BH3 domain of BAX, and allosteric release of the C-
terminal α-helix from the canonical pocket, all of which culminate in BAX membrane insertion 
and permeabilization92. Importantly, the self-propagation mechanism of BAX activation was 
analyzed by employing BAX SAHB, corresponding to the BH3 domain of BAX. Just like BIM 
SAHB, BAX SAHB was able to activate BAX in the context of mitochondrial apoptosis, and 
triggered BAX auto-activation at the same novel trigger site. These studies highlighted the 
capacity of stapled peptides to generate new insight into dynamic protein mechanisms and 
conformational changes, particularly when conventional NMR or X-ray crystallographic studies 
are not achievable. 
Recently, another chemical modification was employed to expand the utility of stapled 
peptides into proteomic and interactome research. Photoreactive stapled BH3 peptides were 
engineered to contain a benzophenone moiety (4-benzophenylalanine, Bpa) in the form of an 
amino acid side chain through conservative aromatic substitution155. This moiety is capable of 
covalently crosslinking to protein targets upon UV irradiation and can covalently trap both static 
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and dynamic protein binding partners, such as BCL-XL and BAX, respectively. These 
photoreactive SAHBs, or pSAHBs, were able to precisely localize the binding site on the target 
protein following crosslinking and nano-LC-MS/MS analysis, which identified the pSAHB-
crosslinked fragments of the interaction site. Attaching a biotin affinity tag to the photoreactive 
peptide enabled enrichment for the crosslinked species, making the LC-MS/MS analysis 
possible. The versatility of peptides and their chemistries make them invaluable, sophisticated 
chemical biology tools that can be applied to biologically relevant questions spanning protein 
interactomes, molecular biology, biochemistry, and structure-function mechanistic analyses. 
 
Chemical cross-linking and proteomics for structural discovery 
Biochemical and mechanistic studies of protein complexes rely heavily on structural 
information. Sophisticated X-ray crystallographic techniques, including recent advances for 
membrane proteins, have contributed enormously to the progress in our understanding of 
biological mechanisms156,157. A complementary approach for crystallographic studies is protein 
NMR spectroscopy, which provides invaluable information about protein behavior in solution 
and dynamic changes associated with conformational alteration. Unfortunately this technique is 
limited by the maximum size of the protein under investigation158. 
Both of these structural methods usually require large quantities of protein, and 
significant optimization of expression and purification: there is often a multiyear gap between 
the understanding of a protein’s biological importance and the availability of its refined structure. 
This reality has spurred significant interest in techniques that would expedite the delivery of 
structural information on proteins and their complexes in a relatively short time frame, even if 
the resolution is partially compromised. Chemical crosslinking for mass spectrometry-based 
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identification of protein interactions and binding sites has been one of the most important 
alternativetechnologies in this arena, especially considering the speed and sensitivity of MS 
analyses (theoretically up to femtomolar scale). If protein reactive groups are in close proximity, 
they can undergo covalent linkage. Trypsinolysis and LC-MS/MS of the peptidic mixture allows 
the identification of specific crosslinking residues on protein complex surfaces. The identified 
crosslinked peptides provide a dataset of distance constraints, much like NOEs in protein NMR, 
ultimately yielding information on binding surface topologies. 
Key advances in this area lie in the ability to identify by mass spectrometry the low-
abundant crosslinked peptides in the presence of the significantly more abundant native peptides 
that represent the “background.” Availability of sophisticated instrumentation (e.g., Orbitrap 
instruments159) and analytical software enabled significant technological improvements. 
However, a seminal issue is the choice of an optimal chemical crosslinker that is reactive under 
mild and native conditions to allow for good yields, yet selective enough to avoid artifacts. Most 
chemical crosslinkers are limited by the intrinsic protein chemistry that reacts with a limited 
number of amino acid side chains, limiting the breadth of crosslinking opportunities in the 
protein target. 
The two most common protein reactive groups employed for crosslinking are the amine 
group of lysine and the thiol group of cysteine. By using activated esters for lysines, (such as 
DSS160), or Michael addition reactions for cysteine crosslinking (e.g., with maleimides161), one 
can obtain sufficiently high yields of crosslinked species. The major drawback of this approach 
is that proteins typically contain relatively few lysine and cysteine functionalities, dramatically 
decreasing the resolution of the binding site information obtained; covalent modifications of 
lysine prevent efficient digestion by common proteases, such as trypsin. Another approach 
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involves carboxyl functionalities of protein side chains (aspartic and glutamic acids) that can be 
activated by incubation with carbodiimide and crosslinked by a diamine crosslinker162. Using 
this approach, typical yields are low due to hydrolysis of the activated ester in the aqueous 
media. 
Introducing non-natural amino acid functionalities into the protein or peptide sequence, 
either by synthesis or by genetic mutation, allows for highly specific crosslinking reactions and 
even potential in vivo use. Azido- and alkynyl functional groups have been used for Huisgen 1,3-
dipolar cycloaddition to form 1,2,3-triazole links163,164. Ketogroups have been introduced with 
subsequent crosslinking by hydrazides165. Finally, photoreactive crosslinkers that intercalate into 
local C-H bonds irrespective of side chain composition have also been employed. For example, 
benzophenone, diazirine and aryl azide side groups have all been used for photoaffinity labeling. 
Among these groups, only benzophenone has the important advantage of its UV- induced radical 
being reversible in the presence of water, which allows the UV-sensitive moiety to undergo 
sequential rounds of photoactivation until successful carbon-carbon crosslinking is achieved166. 
In addition to increasing the chemical yield of crosslinking reactions, several additional 
strategies have been employed to enrich for low-abundant crosslinked peptides, such as 
incorporation of affinity tags155 or bio-orthogonal chemical “handles”167. Other approaches 
include introducing a cleavable ion reporter tag168 or using isotopic labeling for high-confidence 
mass spectrometry identification of crosslinked peptides. 
 
Summary 
α-Helices are a common structural motif that mediates protein-protein interactions. 
Reconstituted short α-helical peptides corresponding to key interaction domains are useful 
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research tools, as well as promising prototype therapeutics. Several common strategies exist to 
stabilize the α-helical shape of peptides once taken out of context from the full-length protein 
and unfolded in solution. One of the most successful approaches has been all-hydrocarbon 
stapling of installed olefinic peptide side chains that are one or two helical turns apart. Stapled 
peptides serve as in vivo agents that target previously intractable pathways, including NOTCH, 
p53, Wnt, and BCL-2 family signaling networkss. As versatile research tools, stapled peptides 
can be chemically modified to incorporate affinity tags, fluorescent probes, and photoreactive 
crosslinker side chains, all of which facilitate their use as research tools to uncover the structures 
and biochemical functions of medically-relevant protein-protein interactions. 
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Production of Full-Length Monomeric BAK 
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Abstract 
BCL-2 family members BAX and BAK execute apoptosis in response to stress stimuli by 
porating the mitochondrial outer membranes and releasing apoptogenic factors. Despite this 
central role as a critical control point of apoptosis, the biochemical mechanisms underlying BAX 
and especially BAK activation are poorly understood. 
The longstanding inability to express full-length BAK as a recombinant protein has 
precluded a complete biochemical and structural dissection of its activation mechanism.  Here, I 
report the successful production of monomeric, full-length BAK (FL-BAK) by increasing the 
solubility of its carboxy-terminal surface through point mutagenesis. 
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Introduction 
 
BAK is a member of the BCL-2 protein family that regulates programmed cell death, or 
apoptosis.  BAK resides as an inactive monomer in the outer membrane of the mitochondria, the 
energy-generating organelle of the cell, until stimulated by cellular stress to undergo 
conformational activation. The activated BAK protein self-associates to form pores in the 
mitochondrial outer membrane, allowing the release of critical signaling factors that drive the 
apoptotic process.  Because BAK activation is one of the ultimate control points for apoptosis, 
the elusive mechanisms underlying BAK regulation and channel formation remain a research 
area of high priority in the cell death field.  The longstanding inability to express full-length 
BAK as a recombinant protein has precluded a complete biochemical and structural dissection of 
its activation mechanism. 
BAK shares functional homology with another BCL-2 family protein named BCL-2–
associated X or BAX.  Each protein contains an essential α-helical motif, termed BCL-2 
homology domain 3 (BH3), which is required for oligomerization-based killing activity.  
Apoptosis is blocked when exposed BAK and BAX BH3 domains are sequestered in a groove on 
the surface of anti-apoptotic BCL-2 family proteins1.  This mode of BAK and BAX suppression 
is so effective in preventing apoptosis that cancer cells are known to hijack and amplify this 
natural regulatory mechanism to enforce pathologic cell survival. Indeed, major efforts are 
underway to pharmacologically disrupt these inhibitory BAK and BAX interactions in order to 
reactivate the death pathway in human cancer.  Although much is known about how BAK and 
BAX are blocked through this canonical “BH3-in-groove” interaction, the mechanisms that 
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activate BAK and BAX, and whether BAK and BAX are directly activated in the first place, 
have been the subject of much debate. 
In recent years, tremendous progress has been made in deciphering thestructure, 
biochemical behavior, and activation patterns and mechanisms of pro-apoptotic BAX, owing in 
large part to the successful isolation of BAX in a pure monomeric form.  Full-length recombinant 
BAX was successfully employed in NMR studies to solve its solution structure2. Much less is 
known about BAK, because as a membrane protein, it has been refractory to expression and 
purification in monomeric form3. To our knowledge, the successful production and purification 
of the full-length monomeric form of BAK has not been achieved. 
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Results 
 
Production of C-terminally truncated BAK 
Because BAK is a membrane protein, there are intrinsic difficulties associated with its 
production and purification, including toxicity for heterologous expression (E.coli), low 
expression levels, and aggregation upon purification4. A standard approach for purification of 
membrane proteins has been truncation of their membrane domains, especially if it is clearly 
identifiable and does not represent the bulk of the protein. In the case of BAK protein, its C-
terminal helix, α9, is the hydrophobic helix that anchors it in the mitochondrial outer 
membrane5. I first eliminated this helix and expressed the truncated form as a GST-fusion, 
followed by affinity purification on GST beads, thrombin cleavage to remove the tag, and size 
exclusion chromatography (FPLC). The elution profile is shown on Figure 2.1, A. Gratifyingly, 
this approach allowed us to isolate large quantities of BAKΔC. Unfortunately, this protein was 
not functional as assessed by liposomal release assay, either alone or in combination with a BH3-
only activator protein tBID, using BAKΔC concentrations of up to 5 µM (data not shown). Based 
on these data, I concluded that BAK’s hydrophobic C-teminal helix is critical to its function. 
Thus, I set out to explore experimental approaches for producing full-length BAK. 
 
Screening different conditions for full-length BAK production and purification 
Having verified the importance of the full-length form of BAK for biochemical and 
functional analysis, we began screening different conditions for full-length BAK production. 
Several variable parameters were explored: expression vector/fusion tag; temperature; and 
bacterial expression strain, all with limited success.  
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Figure 2.1. Expression and purification of select BAK mutant constructs. (A) Size exclusion 
chromatography (SEC) profile of BAKΔC demonstrates successful production of the BAKΔC 
monomer. (B) SEC profile of wild-type full-length BAK reflects the inability to isolate BAK 
monomer. (C) SEC elution profile of BAK C14S/C154S demonstrates that Cys to Ser 
substitutions did not remedy the inability to produce BAK monomer. (D, E) SEC elution profiles 
of proline-modified BAK proteins: BAK P184G (D) and BAK P7S/P9S/P10S (E). (F-I) SEC 
elution profiles of C-terminally modified BAK proteins: BAK I192S/F193S/F206S/F207S (F);  
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Figure 2.1 (Continued). 
 
BAK I192K/I193S (G); BAK V196D (H); BAK I192K/F193S/V196D (I). Only triply mutant 
BAK I192K/F193S/V196D (hereafter referred to as FL-BAK) resulted in the successful isolation 
of a monomeric BAK species. 
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The summary of tested conditions is provided in Table 2.1. Based on our findings, we 
decided to focus our efforts on a chitin binding domain fusion tag-containing expression system, 
as it provided the most promising results for BAK; it is also known to be the system of choice for 
producing full-length BAX. 
 
Point mutagenesis approach to the production of a full-length form of BAK 
Introducing point mutations into the protein sequence can stabilize protein structure and 
promote the expression of a stable monomeric preparation4,6. One common strategy is to remove 
the cysteines from the protein sequence by substituting serines or other amino acids. Since 
cysteines promote disulfide bond formation, removing them can stabilize the protein by 
preventing its aggregation. Unfortunately, replacing cysteines with serines did not provide the 
desired effect for BAK (Figure 2.1, B and C), so we turned to alternative strategies. 
Elimination of a proline residue at a kink between the C-terminal pocket and the α9 helix 
of BAX was previously shown to dramatically stabilize the monomeric form of BAX 7. By 
analogy, we mutated the corresponding proline in full-length BAK (Figure 2.1, D) and several 
prolines at the N-terminal unstructured region of the BAK protein (Figure 2.1, E). However, 
none of these substitutions produced significant improvements in expression or purification. 
A prominent distinction between BAX and BAK is their respective cytosolic vs. 
mitochondrial outer membrane localization, which at least in part, is driven by the disposition of 
the proteins’ C-terminal α-helices. Whereas the BAX α9 helix is tightly bound to its canonical 
binding groove8, the corresponding α-helix in BAK is constitutively released for mitochondrial 
outer membrane insertion. This structural and functional difference between the two α-helices is 
reflected by a comparatively more hydrophobic BAK than BAX α9.  We reasoned that the 
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Table 2.1. Purification systems employed for production of full-length, monomeric BAK. 
 
 pTYB4 / Chitin binding 
domain (C-terminal) 
 pTYB11 / Chitin binding 
domain (N-terminal) 
 pGEX4B / GST tag 
 pGEV2 / GB1 tag 
Vector/tag 
 pET system / His-tag (C- 
or N-terminal) 
 BL21(DE3) 
 Arabinose-inducible cells 
 Rosetta 
Host strain 
 BL21 Origami 
 37°C 
 30°C 
 22°C 
Temperature 
 14°C 
 From soluble fractions Purification 
 Refolding from inclusion 
bodies 
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increased hydrophobicity of BAK’s C-terminus may account for its membrane tropism and 
propensity to aggregate upon bacterial protein expression, precluding the isolation of full-length 
monomer.  To surmount this challenge, I modified the surface of BAK α9 by introducing point 
mutations to better match the amphipathic character of BAX α9. Most of the substitutions did 
not yield the desired monomeric peak on the FPLC trace (Figure 2.1, F-H). However, one triple 
mutant construct produced the full-length monomeric BAK (Figure 2.1, I), and is described 
below. 
 
Production of full-length, monomeric BAK 
The successful production of full-length monomeric BAK resulted from converting the 
hydrophobic Phe193 residue of BAK into a hydrophilic Ser, and replacing the hydrophobic 
Ile192 and Val196 pair with charged residues Lys and Asp, respectively, yielding a surface salt 
bridge (Figure 2.2, A). I employed the pTYB4 vector to generate a chitin binding domain fusion 
protein of murine BAK I192K/F193S/V196D (hereafter referred to as full-length BAK [FL-
BAK]). The fusion protein was expressed in E. Coli BL21 bacteria, isolated by chitin column 
chromatography, and subjected to dithiothreitol (DTT)-based intein tag removal, as reported8,9.  
The elution profiles of wild-type vs. triply mutagenized full-length BAK were compared by size 
exclusion chromatography (SEC).  Whereas the wild-type construct yielded predominantly an 
oligomeric peak accompanied by a small dimeric peak, the α9-mutagenized construct 
additionally produced the desired monomeric peak (Figure 2.2, B). The monomeric fraction (11-
12 mL elution volume) migrated as a 23 kD protein by SDS PAGE, and the identity of FL-BAK 
protein was confirmed by anti-BAK western blot analysis (Fig. 2.2, B) and MS/MS of the 
electrophoresed band (Fig. 2.2, C). 
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Figure 2.2. Expression and purification of recombinant, full-length, and monomeric BAK. 
(A) The α9 helix of BAK was subjected to triple mutagenesis (I192K/F193S/V196D) in order to 
increase its hydrophilicity and better match that of soluble, full-length BAX.  The pictured model 
structure of BAK was calculated based on the solution structure of BAX using Modeller 
software10, with BAK α9 colored blue. The hydrophobic, hydrophilic, positively charged, and 
negatively charged residues of the BAK and BAX α9 helices are colored yellow, green, blue, 
and red, respectively. (B) A comparison of the SEC elution profiles of BAK and BAK  
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Figure 2.2 (Continued). 
 
I192K/F193S/V196D (FL-BAK) demonstrates that mutagenesis enabled the isolation of a 
monomeric species (11-12 mL fractions).  Silver staining and anti-BAK western analysis of the 
electrophoresed FL-BAK fractions documented the isolation of monomeric BAK protein (~23 
kDa). (C) The identity of the isolated, monomeric protein was confirmed to be FL-BAK by mass 
spectrometry analysis. Tryptic sites are highlighted by the arrowheads and the FL-BAK 
sequences identified by LC-MS/MS are colored blue. 
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FL-BAK induces apoptosis at a similar level as wild type BAK when transfected into cells  
Importantly, I confirmed that this triple mutagenesis of BAK did not alter its functional 
activity, as evidenced by equivalently decreased viability of etoposide and staurosporine-treated 
Bax-/-Bak-/- iBMK11 cells upon expression of wild-type or the triply mutated full-length BAK 
(Fig. 2.3). 
 
Summary 
By employing structure-guided mutagenesis, I successfully generated, for the first time, 
pure, full-length, monomeric BAK by introducing the point mutations I192K/F193S/V196D. I 
confirmed the identity of the protein by mass spectrometry and western analysis, and 
documented its functionality in a cellular context by transiently expressing FL-BAK in Bax-/-Bak-
/- iBMK cells, which otherwisemanifest a severe deficiency in mitochondrial apoptosis. Upon 
transient expression and stimulation with cytotoxic drugs, triply mutant FL-BAK and wild-type 
BAK induced cell death at identical levels. 
 
Methods 
Expression and purification of full-length BAK 
Production of monomeric, full-length BAK (FL-BAK) was achieved by introducing the 
point mutations I192K/F193S/V196D into the native mouse BAK sequence (Fig. 2.2, A; NCBI: 
NP_031549.2), which was subcloned into the pTYB4 vector (New England Biolabs) using NcoI 
and SmaI restriction sites. PCR-based site-directed mutagenesis was confirmed by DNA 
sequencing. The chitin binding domain fusion construct of FL-BAK was expressed in  
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Figure 2.3. Equivalent pro-apoptotic activity of wild-type and FL-BAK.   
(A) BAX/BAK-deficient immortalized baby mouse kidney epithelial (iBMK) cells reconstituted 
with wild-type BAK or FL-BAK were treated with etoposide (10 mM) or staurosporine (STS, 
100 nM), and cell viability assessed by CellTiter-Glo at 24 hours. Bax-/-Bak-/-, Bax-/-Bak-/- plus 
vector alone, and wild-type iBMK cells served as controls.  Untreated controls were also 
included for all cell lines tested.  Data are mean ± SEM for experiments performed in at least  
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Figure 2.3 (Continued). 
 
triplicate. (B) BAK expression levels in the indicated cell lines were determined by anti-BAK 
western analysis. Whereas Bax-/-Bak-/- and Bax-/-Bak-/- plus vector iBMK cells showed no 
response to the etoposide or STS treatment, cells with introduced wild-type and triply mutant 
BAK (FL-BAK), which express at similar levels, exhibited equivalent impairment of viability in 
response to the pro-apoptotic stimuli. Of note, wild-type iBMK cells demonstrated the most 
robust response to etoposide and STS treatment, consistent with their expression of relatively 
higher levels of native BAK (in addition to the presence of native BAX). 
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BL21(DE3) E. coli and induced with 1 mM IPTG at 18°C overnight. Collected bacterial pellets 
were resuspended in lysis buffer (20 mM Tris, 250 mM NaCl, pH 7.6), lysed by 
microfluidization (Microfluidics M-110L), and centrifuged at 45,000 rpm for 1 h at 4°C 
(Beckman L-90K). The cleared cellular lysates were subjected to chitin affinity resin (New 
England Biolabs) chromatography followed by overnight on-bead intein-tag cleavage using 50 
mM DTT.  FL-BAK was eluted with lysis buffer, concentrated, and then subjected to size-
exclusion chromatography (GE Life Sciences) at 4°C using 20 mM Hepes pH 7.8, 150 mM KCl 
buffer conditions.  FL-BAK and its cysteine-mutant derivative were used immediately upon 
isolation, without further storage. FL-BAK C14S/A128C/C154S/L198C was maintained in the 
oxidized state by exposure to 2 mM glutathione disulfide (GSSG), whereas reduction of the 
disulfide tether was accomplished by 1 h incubation in 10 mM dithiothreitol (DTT).  
Recombinant full-length BAX and BCL-XLΔC were produced as described8,9 and tBID was 
purchased from R&D Systems. Protein concentrations were determined by Bradford assay 
(Biorad). 
 
iBMK transfection and cell viability assay.  
Immortalized baby mouse kidney epithelial (iBMK) cells deficient in BAX and BAK11 
were transfected with the pORF mammalian expression vector alone or with the corresponding 
plasmid containing wild-type or FL-BAK using lipofectamine 2000 (Invitrogen), according to 
the manufacturer’s protocol.  The pORF plasmid containing wild-type murine BAK was 
purchased from Invivogen, and that containing FL-BAK was generated by PCR-based site-
directed mutagenesis and confirmed by DNA sequencing. bax-/-bak-/- iBMK cells were plated in 
96-well plates (4x104 cells/well) in Dulbecco’s Modified Eagle Media (DMEM) supplemented 
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with penicillin/streptomycin, glutamine, 2 mM dithiothreitol and 5% FBS. A mixture of plasmid 
DNA (0.2 µg) and 0.5 µl lipofectamine was added to each well, followed by 24 hour incubation. 
The transfected cells and control wild-type and bax-/-bak-/- iBMK cells, were then treated with 
staurosporine (STS, 100 nM) or etoposide (10 µM), and cell viability was measured at 24 hours 
by CellTiter-Glo assay (Promega), according to the manufacturer’s instructions. 
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Abstract 
The longstanding inability to express full-length BAK as a recombinant protein has 
precluded a complete biochemical and structural dissection of its activation mechanism. The 
‘indirect activation model’ and ‘direct activation model’ were proposed to explain BAK and 
BAX membrane-permeabilization activity. The former postulates that BAX and BAK 
spontaneously oligomerize as soon as apoptotic inhibition is relieved, whereas the latter suggests 
that a direct triggering event, most likely by the BH3-only proteins, is necessary to initiate BAK 
and BAX activation. 
I employed FL-BAK to address these unresolved questions. I find that soluble FL-BAK 
auto-translocates to isolated mitochondria, demonstrating a preference for the membrane 
environment that is consistent with the relative subcellular distributions of BAX and BAK in 
vivo. Translocation of FL-BAK does not permeabilize the mitochondria unless a BH3-only 
activator is also present, indicating that a definitive activation step is required either in the form 
of a direct trigger or inhibition of suppressive protein interactions. I found that the BH3-only 
protein tBID, or its essential BH3 helix in the form of a stapled BID BH3 peptide, activates and 
functionally oligomerizes FL-BAK in the absence of any other factors, definitively 
demonstrating a direct activation mechanism for full-length BAK. I used FL-BAK and a stapled 
BID BH3 peptide to measure the direct and sequence-dependent interaction between BAK and 
an activating BH3 helix. 
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Introduction 
The primary function of pro-apoptotic BCL-2 family member proteins BAK and BAX is 
to execute mitochondrial apoptosis in response to stress stimuli1-3. In response to the apoptotic 
signal, activated BAX and BAK self-associate to form pores in the outer mitochondrial 
membrane 4,5, resulting in propagation and execution of the cell death cascade by releasing 
apoptogenic factors, such as cytochrome c, from mitochondria, thus triggering an irreversible 
capase-mediated cell death program.  
BAK and BAX activation mechanisms have been the focus of much debate. Two models 
were proposed: “direct activation” and “indirect activation” 6,7. The indirect activation model 
posits that BAK and BAX proteins exist in homeostatically primed forms and as soon as 
antiapoptotic inhibition is relieved, BAX and BAK proceed to form oligomers8,9. However, in 
the proposed indirect model, the stimulus responsible for the initial BAX and BAK priming is 
not explained, and only a small fraction of BAX and BAK is bound to antiapoptotic proteins in 
healthy, non-apoptotic cells10. The direct activation model suggests that in addition to preventing 
anti-apoptotic protein inhibition, a direct triggering interaction, most likely by the BH3-only 
proteins, is also necessary to activate BAK and BAX11.  
Several studies carefully examined BAX behavior and activation properties, confirming a 
critical role for direct triggering of BAX in initiating its apoptotic function12,13. However, little is 
known about the direct activation mechanism for BAK, an equally important mediator of cell 
death. Residing in the mitochondrial outer membrane environment8, BAK may be one step closer 
to the activated state, as compared to BAX, which must first translocate from the cytosol to the 
mitochondrial membrane14,15. With FL-BAK in hand, I aimed to interrogate the BAK activation 
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mechanism and to clearly distinguish between direct and indirect BAK activation mechanisms in 
driving apoptosis. 
 
 
Results 
FL-BAK automatically translocates to mitochondrial membranes, but does not 
permeabilize them without an additional stimulus 
With recombinant, monomeric FL-BAK in hand, I first sought to evaluate its biochemical 
behavior in aqueous solution containing isolated Bak-/- mouse liver mitochondria (MLM).  
Whereas recombinant, monomeric BAX requires ligand stimulation for mitochondrial 
translocation16, I observed that FL-BAK auto-translocated to MLM in a dose-responsive fashion 
(Fig. 3.1, A).  In contrast to ligand-stimulated BAX translocation12, the auto-translocation of FL-
BAK was not accompanied by cytochrome c release (Fig. 3.1, B). These data highlight the 
successful production of full-length monomeric BAK, which exhibits a natural preference for 
partitioning to mitochondria.  Strikingly, this translocation is not accompanied by mitochondrial 
outer membrane permeabilization (MOMP), suggesting that a further activation step is required.  
 
BH3-only activator tBID triggers BAK oligomerization and cytochrome c release from 
mouse liver mitochondria 
I subjected the mixture of FL-BAK and Bak-/- MLM to the activator BH3-only protein 
tBID. I observed reciprocal dose-responsive activation of tBID-induced FL-BAK-mediated 
cytochrome c release, indicative of functionally intact BAK protein (Fig. 3.2, A and B). I 
monitored BAK oligomerization by using a chemical crosslinking approach. A small molecule  
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Figure 3.1. FL-BAK displays a natural tropism for the membrane environment. 
(A) Upon exposure to isolated Bak-/- mouse liver mitochondria, FL-BAK dose-responsively 
translocated to the mitochondria-containing pellet fraction, as detected by anti-BAK western 
analysis. (B) Auto-translocation of FL-BAK to the mitochondrial fraction did not induce 
cytochrome c release from the pellet to the supernatant, as measured by anti-cytochrome c 
western analysis. 
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Figure 3.2. BH3-only protein tBID triggers FL-BAK-dependent mitochondrial release. (A, 
B) tBID dose-responsively triggered FL-BAK-mediated cytochrome c release from isolated  
Bak-/- mitochondria, as measured by cytochrome c ELISA.  Likewise, FL-BAK dose-
responsively induced cytochrome c release upon exposure to fixed dose tBID. No release was  
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Figure 3.2 (Continued). 
 
observed upon exposure of the mitochondria to tBID or FL-BAK alone. Data are mean ± SD for 
experiments performed in duplicate and repeated at least three times using independent FL-BAK 
preparations with similar results. (C) tBID-induced and FL-BAK-mediated liposomal and 
mitochondrial release coincides with FL-BAK oligomerization. FL-BAK (500 nM) was 
incubated with Bak-/- mouse liver mitochondria in the presence or absence of tBID (100 nM), 
followed by a 15 minute incubation with bismaleimidohexane (BMH, 100 mM). After quenching 
with DTT, the reaction was subjected to SDS-PAGE and anti-BAK western analysis.  
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bifunctional cross-linker was applied to either a mixture of FL-BAK with tBID or FL-BAK alone 
in the presence of mitochondrial preparations, and the efficiency of oligomerization was assessed 
in each case by SDS-PAGE and western blotting. The observed FL-BAK oligomerization 
correlated with tBID-triggered and FL-BAK-mediated mitochondrial permeabilization (Fig. 3.2, 
C). 
 
Direct activation of FL-BAK by tBID 
Whereas the MLM experimental framework does not distinguish between tBID-induced 
direct activation of FL-BAK vs. derepression of FL-BAK as a result of anti-apoptotic inhibition 
by tBID, I further employed a reductionist liposomal system to evaluate FL-BAK release activity 
in the absence of other mitochondrial factors.  Whereas incubating ANTS/DPX 
(fluorophore/quencher)-encapsulated liposomes with tBID or FL-BAK alone yielded little to no 
release of entrapped fluorophore, the combination of tBID and FL-BAK induced dose- and time-
responsive liposomal release (Fig. 3.3, A). I confirmed by chemical crosslinking analysis that 
tBID-induced and FL-BAK-mediated liposomal release was accompanied by oligomerization of 
FL-BAK (Fig. 3.3, B). SEC analysis of the liposomal reaction mixtures further documented 
conversion of FL-BAK from a monomeric to an oligomeric form upon tBID exposure, with the 
majority of tBID remaining monomeric, consistent with the proposed “hit and run” mechanism 
for BH3-induced direct BAX/BAK activation17 (Fig. 3.3, C, D).  
 
The BID BH3 domain is responsible for direct BAK activation 
To specifically link the FL-BAK-triggering activity of tBID to its BH3 domain, we 
generated stabilized alpha-helices of BCL-2 domains (SAHBs) modeled after the BID BH3 
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Figure 3.3. tBID triggers FL-BAK-dependent liposomal release. (A) tBID dose-responsively 
induced FL-BAK-mediated liposomal release of entrapped fluorophore, whereas tBID or FL-
BAK alone had little to no effect. Data are representative of at least three independent 
experiments with similar results. (B) BAK-mediated liposomal release coincides with BAK  
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Figure 3.3 (Continued). 
 
oligomerization. FL-BAK (500 nM) was incubated with liposomes in the presence or absence of 
tBID (100 nM) for 30 minutes, followed by a 15 minute incubation with disuccinimidyl suberate 
(DSS, 100 mM).  After quenching with Tris base, the reaction mixture was subjected to SDS-
PAGE and anti-BAK western analysis.  (C – D) Size exclusion chromatography analysis of 
tBID-induced conversion of FL-BAK from monomer to oligomer.  (C) FL-BAK (500 nM) was 
incubated with liposomes and analyzed by SEC after solubilization with CHAPS (0.5%).  SEC 
fractions were collected, subjected to SDS-PAGE, and analyzed by anti-BAK western blotting.  
The elution fractions for molecular weight marker proteins (17, 44, and 158 kDa) are indicated.  
(D) The experiment was repeated with the inclusion of tBID (100 nM) and analyzed as above.  In 
the presence of tBID (100 nm), FL-BAK (500 nM) is partially converted from monomer to 
oligomer after a 30 minute incubation. Of note, tBID predominantly remains in monomeric form, 
consistent with a “hit and run” mechanism for tBID-induced FL-BAK activation.  
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helix12,18 for functional analysis (Fig. 3.4, A).  We first performed fluorescence polarization (FP) 
binding analyses using FITC-BID SAHBs and FL-BAK, and, for the first time, detected and 
quantified the direct interaction between BID BH3 and full-length BAK.  Whereas two 
differentially stapled BID SAHBs engaged FL-BAK with KD values of 80-95 nM, single G94E 
point mutagenesis of the α-helical interface abrogated binding activity (Fig. 3.4, B). 
Correspondingly, BID SAHBs dose- and time-responsively activated FL-BAK-mediated 
liposomal release (Fig. 3.4, C and D), whereas little to no activity was observed for the point 
mutant SAHB (Fig. 3.4, E). Taken together, these data document that recombinant and 
monomeric FL-BAK is functionally active and can be induced to porate membranes as a result of 
direct and measurable interactions with BID BH3.   
 
Summary 
Having generated the full-length form of BAK for the first time, we show that it 
recapitulates BAK’s native behavior. BAK translocated to mitochondria without a stimulus, and 
released cytochrome c upon tBID treatment. By employing a liposomal release assay we were 
able to distinguish between direct and indirect activation of BAK, and definitively conclude that 
in order to oligomerize and permeabilize lipidic membranes, BAK requires direct triggering, 
such as by BH3-only proteins. 
 
Methods 
SAHB synthesis and characterization 
Peptide synthesis, hydrocarbon stapling by olefin metathesis, and derivatization with 
FITC and biotin were performed according to our established methods19,20. All peptides were  
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Figure 3.4. BID SAHBs bind to FL-BAK in a sequence-dependent manner and directly 
trigger FL-BAK activation. (A) Stabilized alpha-helix of BCL-2 domains (SAHBs) 
corresponding to the BH3 motif of BH3-only protein BID were generated by substituting non- 
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Figure 3.4 (Continued). 
 
natural amino acids bearing olefin tethers at i, i+4 positions followed by ruthenium-catalyzed 
olefin metathesis. G94E point mutagenesis of the hydrophobic binding interface yielded a 
negative control SAHB for biochemical studies. X, non-natural amino acid; B, norleucine 
(substituted for methionine to avoid thioether-based interference with ruthenium catalysis).  
(B) BID SAHBs A and B bound to FL-BAK with nanomolar affinity, whereas G94E point 
mutagenesis abrogated the interaction, as measured by fluorescence polarization assay. Data are 
mean ± SEM for experiments performed in at least duplicate and repeated three times with 
independent preparations of FL-BAK.  (C - E) BID SAHBs A and B dose-responsively induced 
FL-BAK-mediated liposomal release of entrapped fluorophore, whereas BID SAHBB G94E, or 
BID SAHBs or FL-BAK alone, had little to no effect. Data are representative of at least three 
independent experiments with similar results. 
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purified by LC/MS to >95% purity and quantified by amino acid analysis. Photoreactive SAHBs 
(pSAHBs) were generated as described21 by incorporating Fmoc-L-p-benzoyphenylalanine 
(EMD Biosciences) at the indicated locations in the peptide sequence. 
 
Mitochondrial translocation assay 
Bak-/- mitochondria were isolated from the livers of Bak-/- mice as previously reported12, 
resuspended in experimental buffer (125 mM KCl, 10 mM Tris-MOPS [pH 7.4], 5 mM 
glutamate, 2.5 mM malate, 1 mM KPO4, 10 uM EGTA-Tris [pH 7.4]), and then treated with the 
indicated concentrations of freshly purified FL-BAK. After 90 min incubation at room 
temperature followed by tabletop centrifugation at 5500 x g, the supernatant and pellet fractions 
were separated and subjected to SDS-PAGE and immunoblotting using BAK NT (Millipore) and 
cytochrome c (BD Pharmingen) antibodies. 
 
Mitochondrial cytochrome c release assay 
Cytochrome c release assays were performed as previously reported12. Briefly, bak-/- 
mitochondria were incubated with the indicated concentrations of FL-BAK and tBID for 45 min 
at room temperature in experimental buffer (see above). The pellet and supernatant fractions 
were isolated by centrifugation at 3,200 rpm, and cytochrome c quantitated using a colorimetric 
ELISA assay (R&D Systems).  Percent cytochrome c released into the supernatant (%cytocsup) 
from releasable mitochondrial pools was calculated according to the following equation: 
%cytoc=[(cytocsup-cytocbackgr)/(cytoctotal-cytocbackgr)]*100, where background release represents 
cytochrome c detected in the supernatant of vehicle-treated samples and total release represents 
cytochrome c measured in 1% Triton-X 100 treated samples. 
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Liposomal release assay 
The liposomal release assay was adapted from a previously described method22. Large 
unilamellar vesicles (LUVs) were generated from a lipid mixture containing 48% 
phosphatidylcholine, 28% phosphatidylethanolamine, 10% phosphatidylinositol, 10% dioleoyl 
phosphatidylserine and 4% tetraoleoyl cardiolipin (Avanti Polar Lipids).  The lipid mixture (1 
mg aliquots) was prepared from chloroform stocks and dried as a thin film in glass test tubes 
under nitrogen gas and then under vacuum for 15 h. The fluorescent dye ANTS (6.3 mg) and the 
quencher DPX (19.1 mg) were added to 1 mg of dry lipid film, and the mixture resuspended in 
assay buffer (200 mM KCl, 1 mM MgCl2, 10 mM HEPES, pH 7.0). After five freeze-thaw 
cycles (liquid nitrogen/water bath), the lipid mixtures were extruded through a 100 nm 
nucleopore membrane (Whatman) using an Avanti mini extruder, followed by gravity flow SEC 
using a crosslinked Sepharose CL-2B column (Sigma Aldrich). LUVs (10 ml) were treated with 
the indicated concentrations of FL-BAK, tBID, and BID SAHBs, singly and in combination, in 
96-well format (Corning) in a total reaction volume of 100 ml. Fluorescence was measured from 
t =0 (F0) to t =2 h, and then Triton X-100 was added to a final concentration of 0.2% (v/v) 
followed by measurement of fluorescence for an additional 10 min to determine maximal release 
(F100).  Percent ANTS/DPX release was calculated as ((F – F0)/(F100 – F0)) × 100. 
 
Fluorescence polarization binding assay 
FP assays were performed as previously described23.  Briefly, FITC-BID SAHBs (15 nM) 
were incubated with the indicated serial dilution of FL-BAK protein in binding buffer (50 mM 
Tris, 100 mM NaCl, pH 8.0) until equilibrium was reached.  FP was measured using a 
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SpectraMax M5 microplate reader (Molecular Devices).  Dissociation constants (KD) were 
calculated by nonlinear regression analysis of dose-response curves using Prism software 
(GraphPad).   
 
Fractionation of FL-BAK to monitor its oligomerization 
FL-BAK (500 nM) was incubated with liposomes in the presence or absence of tBID 
(100 nM) at room temperature for 30 minutes.  Following solubilization by CHAPS (0.5%), the 
mixture was subjected to size exclusion chromatography (SEC) at 4°C in 20 mM Hepes pH 7.8, 
150 mM KCl, 0.5% CHAPS. The fractions were collected, subjected to SDS-PAGE, and then 
analyzed by western blot using BAK (BAK NT, Millipore) and BID (FL-195, Santa Cruz) 
antibodies. 
 
Chemical crosslinking analysis of FL-BAK upon tBID-induced liposomal and 
mitochondrial release 
FL-BAK (500 nM) was incubated with liposomes or Bak-/- mouse liver mitochondria in 
the presence or absence of tBID (100 nM) at room temperature for 30 minutes. Disuccinimidyl 
suberate (DSS) and bismaleimidohexane (BMH) were added to the liposomal and mitochondrial 
mixtures, respectively, at a final concentration of 100 mM, and incubated for 15 minutes.  After 
quenching the liposomal and mitochondrial crosslinking reactions with 1M Tris base and 50 mM 
dithiothreitol (DTT), respectively, the mixtures were subjected to SDS-PAGE and anti-BAK 
western analysis.  
 
Contributions 
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Chapter 4 
 
 
 
Comparative Structural Analysis of the Activation  
of Full-Length Proapoptotic BAK and BAX 
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Abstract 
It has been recently shown that BAX is directly activated by BIM BH3 and the binding 
site was located by NMR spectroscopy1.  Surprisingly, the triggering BH3-binding site on BAX 
is found at the opposite side of the protein from the canonical binding pocket of anti-apoptotic 
proteins. The nature of the binding interaction also differs from that of BH3 engagement of anti-
apoptotic proteins, in that the BAX interaction is a transient, hit-and-run phenomenon.  
Much less is known about BAK, in part due to the inability to obtain full-length protein 
for biochemical and structural studies. Not only was a site for BH3 interaction with BAK 
unknown, but whether BH3-only proteins directly engage BAK to begin with was unknown. 
With full-length BAK in hand, we were in a position to determine if direct BH3 interactions 
occur, and if so, where the site of interaction is located. By applying photoreactive BH3 helices 
and mass spectrometry analysis, we mapped the trigger site for direct BAK activation to its 
canonical BH3-binding pocket located at the C-terminal face of the protein, whereas the same 
ligands crosslinked to the N-terminal BH3 trigger site of BAX.  Thus, BAK and BAX activation 
are initiated by direct BH3 interaction, but at distinct trigger sites.  
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Introduction 
The structural conformations of BCL-2 family of proteins have been an intensive focus of 
cell death research. The interactions between BCL-2 family proteins are mediated by the binding 
of the BH3 domains of proapoptotic BAK, BAX, and BH3-only proteins to the hydrophobic C-
terminal canonical binding pocket, or groove, on antiapoptotic proteins such as MCL-1, BCL-2, 
BCL-XL. Structures of antipoptotic proteins complexed with peptides corresponding to BH3 
domains of other BCL-2 family members all follow described consistent structural pattern2-5. 
The paradigm for antiapoptotic sequestering of the BH3 helices of activated BAK and BAX has 
translated into pharmacological disruption of this interaction to reactivate apoptosis in human 
cancer6-8. 
The interactions of the same BH3-only proteins with BAK and BAX were much more 
elusive, especially in deciphering between the ‘direct’ vs. ‘indirect’ activation models: the 
indirect activation model implied that BH3-only interactions with BAX and BAK may not occur 
in the first place.  
Structural and biochemical analyses of the interactions between full-length recombinant 
BAX and a stapled BIM BH3 helix revealed a novel,  non-canonical BH3 interaction site at the 
confluence of BAX α-helices 1 and 6, which has been termed a trigger site for BH3-mediated 
direct BAX activation1. Upon interaction with a triggering BH3 ligand, BAX undergoes a major 
conformational change that includes allosteric release of its C-terminal helix for mitochondrial 
translocation and exposure of its BH3 domain, which both propagates BAX activation and 
results in functional oligomerization within the mitochondrial outer membrane9.  
In contrast to BAX, full-length BAK has been refractory to protein expression and 
purification10, precluding the corresponding structural and biochemical studies using fully intact 
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recombinant protein. Instead, truncated forms of BAK have been used11-14, documenting BAKΔC 
dimeric structures with severely occluded canonical pocket11,12 and the interactions of select BH3 
peptides to the canonical pocket region of BAKΔC13,14. 
By employing FL-BAK, we aimed to interrogate its BH3 binding capability and site of 
activation, and determine whether the N-terminal trigger site found in BAX also exists on BAK, 
and/or whether the C-terminal canonical pocket plays a role in direct BAK activation. 
 
Results 
Photoreactive BID SAHBs localize the canonical BH3 binding pocket of BCL-XL 
We previously developed photoreactive SAHBs (pSAHBs), containing differentially 
localized benzophenone moieties, as novel tool reagents for covalently trapping protein 
interactors and explicitly localizing the sites of intercalation by mass spectrometry15. pSAHBs 
are ideally suited for rapid binding site identification in the absence of protein solution or crystal 
structures. Here, we synthesized and deployed a panel of BID pSAHBs (Fig. 4.1, A) to locate the 
BH3 interaction site on FL-BAK. To validate the binding specificity and utility of BID pSAHBs 
1-3, we first conducted crosslinking analysis with anti-apoptotic BCL-XLΔC, for which 
definitive structures are known. We found that the differentially-placed benzophenone moieties 
in each BID pSAHB crosslinked to discrete subregions of the canonical BH3 binding pocket, 
precisely corresponding to the established structures of BH3 helix/BCL-XLΔC complexes (e.g. 
PDB ID# 2YJ1, 3FDL, 1BXL, 3PL7) (Fig. 4.1, B-E). 
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Figure 4.1. Photoreactive BID SAHBs localize BH3 interaction sites with high fidelity. 
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Figure 4.1. (Continued). 
 
 (A) Photoreactive stabilized alpha-helix of BCL-2 domains (pSAHBs) modeled after the BH3 
domain of BID were generated for protein capture and binding site identification by replacing 
select native residues with 4-benzoyl-phenylalanine (Bpa), followed by ring closing metathesis 
of olefinic non-natural amino acids installed at i, i+4 positions. To facilitate tryptic digestion of 
pSAHBs into shorter and more identifiable fragments by MS, single arginine substitutions were 
made as indicated, taking advantage of natural sites of homology between the human and mouse 
BID BH3 domains (i.e. H84R, H99R). 
 (B – D) BID pSAHBs 1-3 were incubated individually with antiapoptotic BCL-XLΔC and the 
mixtures subjected to UV irradiation, electrophoresis, excision of the crosslinked protein, trypsin 
proteolysis, and LC-MS/MS analysis. The plots depict the frequency of crosslinked sites 
identified across the BCL-XLΔC polypeptide sequence.  Orange arrowheads indicate trypsin 
digestion sites. (E) Mapping of BID pSAHB-crosslinked amino acids onto the BCL-XLΔC 
structure (PDB ID 2BZW) highlighted the capacity of individual pSAHBs to explicitly localize 
sites of interaction to circumscribed regions along the canonical BH3-binding pocket 
corresponding to the relative N- to C-terminal disposition of benzophenone residues within the 
pSAHB sequence. Docking was performed using crystallography and NMR system solve (CNS) 
within HADDOCK 2.0 16 and results displayed by PYMOL 17. The frequency of crosslinking 
occurrence is reflected on the BCL-XLΔC structure by the color scale for each BID pSAHB (1, 
red; 2, green; 3, blue). 
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Photoreactive BID SAHBs localize the BH3 trigger site on BAK 
Having validated the fidelity of BID pSAHBs 1-3, we next subjected FL-BAK to the 
crosslinking analysis.  Walking the benzophenone moiety from the C- to N-terminus of BID 
pSAHB led to sequential crosslinking of discrete residue clusters along the canonical BH3 
binding pocket of FL-BAK (Fig. 4.2, A-C). Interestingly, BID pSAHB-3, which contained the 
most N-terminal benzophenone substitution also crosslinked to select internal face residues of 
BAK α9, suggesting that the BID BH3 helix directly displaces the C-terminal helix, whose 
hydrophobic face becomes exposed for interaction (Fig. 4.2, C). 
 
Occlusion of the C-terminal BH3 trigger site by disulfide tethering leads to disruption of 
BID BH3 binding to BAK 
We mutated Leu198 of α9 and Ala128 of α5 to cysteine residues, and converted native 
cysteines C14 and C154 to serines, in order to generate a FL-BAK construct in which α9 can be 
reversibly locked into its canonical binding pocket based on redox conditions (Fig. 4.3, A). 
Whereas FITC-BID SAHBB bound to FL-BAK C14S/A128C/C154S/L198C under reducing 
conditions (10 mM DTT), no interaction was observed under oxidizing conditions (2 mM GSSG) 
(Fig. 4.3, B). Of note, the reducing and oxidizing conditions had no effect on the interaction 
between FITC-BID SAHBB and the parental FL-BAK construct (Fig. 4.3, C). Thus, the data 
suggest that when the canonical BH3-binding pocket is blocked by locking the C-terminus in 
place, no further binding can occur between BID SAHB and FL-BAK.  This result stands in 
striking contrast to the biochemical- and NMR-based analyses of the interaction between BIM 
SAHB and BAX, whereby covalent tethering of the BAX C-terminus to its canonical pocket had 
no disruptive effect on BIM SAHB binding, which was maintained at the α1/α6 trigger site9. 
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Figure 4.2. Photoreactive BID pSAHBs localize the BH3 trigger site on BAK to its 
canonical BH3-binding pocket. (A-C) BID pSAHBs 1-3 were incubated individually with  
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Figure 4.2 (Continued). 
 
FL-BAK and the mixtures subjected to UV irradiation, electrophoresis, excision of the 
crosslinked protein, trypsin proteolysis, and LC-MS/MS analysis. The plots depict the frequency 
of crosslinked sites identified across the FL-BAK polypeptide sequence, with crosslinked 
residues mapped onto a calculated model structure of FL-BAK (based on sequence homology to 
BAX) and colored according to the frequency of occurrence for each pSAHB (1, red; 2, green; 3, 
blue).  For BID pSAHBs 1 and 2, which do not crosslink to residues of the C-terminal helix of 
FL-BAK, α9 has been removed from the structure to better visualize the crosslinked residues at 
the surface of the canonical BH3-binding pocket.  For BID pSAHB-3, a side view of FL-BAK is 
also shown in order to demonstrate the localization of crosslinked residues at both the surface of 
the canonical BH3-binding pocket and the inner surface of α9. The latter dataset highlights that, 
after α9 displacement, previously unexposed and inward-facing α9 residues become available 
for interaction with BID pSAHB-3. 
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Figure 4.3. The binding interaction between BID SAHB and FL-BAK requires access to the 
canonical BH3-binding pocket. (A) To determine if the BID SAHB/FL-BAK interaction is 
explicitly dependent on displacement of α9 (blue) and exposure of the canonical pocket, FL-
BAK residues A128 of α5 and L198 of α9 were mutated to cysteines (yellow) and native 
cysteines C14 and C154 were mutated to serines, yielding an α9-tethered FL-BAK construct in 
	   95	  
Figure 4.3 (Continued) 
 
which the C-terminal helix is reversibly locked into its binding pocket by redox conditions. (B) 
Oxidized FL-BAK (C14S/A128C/C154S/L198C) (2 mM GSSG) showed no interaction with 
FITC-BID SAHBB, whereas binding activity was completely restored upon addition of reducing 
agent (10 mM DTT), as assessed by fluorescence polarization assay.  Data are mean ± SEM for 
experiments performed in at least duplicate and repeated at least two times with independent 
preparations of FL-BAK (C14S/A128C/C154S/L198C). (C) In contrast, redox conditions have 
no effect on the binding interaction between FITC-BID SAHBB and FL-BAK.  Data are mean ± 
SEM for experiments performed in at least duplicate and repeated at least two times with 
independent preparations of FL-BAK. 
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The BH3 trigger site is identical in soluble and membrane-bound BAK 
Importantly, we confirmed that BID pSAHB engagement of the canonical BH3-
interaction site likewise occurred in the membrane context. We generated and purified FL-BAK-
embedded and ANTS/DPX-loaded liposomes, confirming by proteinase K digestion and anti-
BAK western blot that FL-BAK was susceptible to proteolysis and thus surface exposed (Fig. 
4.4, A). The FL-BAK-containing liposomes preserved membrane integrity, as reflected by 
release of fluorophore upon Triton X-100 lysis (Fig. 4.4, B), and underwent dose-responsive, 
ligand-triggered release upon exposure to tBID (Fig. 4.4, C).  Having validated the functional 
reconstitution of FL-BAK into liposomes, we then incubated the liposomes with BID pSAHB-1 
in the presence of UV light and subjected the mixture to our MS-based crosslinking analysis.  
Although the crosslinking and site-identification method was less efficient in the liposomal 
context, discrete residues of the FL-BAK canonical pocket were again detected by BID pSAHB-
1 photoaffinity labeling (Fig. 4.4, D).  Thus, we find that whether performed in solution or in the 
membrane environment, BID SAHB directly engages residues of the canonical BH3-binding 
groove of FL-BAK. 
 
Activator BID pSAHBs detect distinct trigger sites for BAK and BAX  
Because photoactivated benzophenone crosslinking may favor stable over transient BH3 
interactions, we sought to further interrogate the BID pSAHB crosslinking results to rule out the 
possibility of an alternative BH3 interaction site on BAK, as discovered for BAX by NMR 
analysis1.  
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Figure 4.4. BID pSAHB-1 crosslinks to discrete residues of the BH3-binding pocket of 
membrane-embedded FL-BAK.  (A) Liposomes generated in the presence of FL-BAK and 
ANTS/DPX were purified by SEC.  (B) Incorporation of FL-BAK was documented by anti-BAK 
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Figure 4.4 (Continued). 
 
western analysis.  Upon treatment with proteinase K, FL-BAK was efficiently proteolyzed, 
consistent with protein exposure at the liposomal surface.  (C) Protein-free and FL-BAK-
embedded liposomes manifested a similar degree of ANTS/DPX release upon lysis with Triton 
X-100, confirming that FL-BAK liposomes maintain membrane integrity and stably encapsulate 
ANTS/DPX.  Data are mean ± SEM for experiments performed in at least duplicate and are 
representative of two independent experiments. (D) FL-BAK liposomes likewise maintained 
signaling functionality, as demonstrated by dose-responsive release of ANTS/DPX upon 
exposure to tBID.  Data are mean ± SEM for experiments performed in at least duplicate and are 
representative of two independent experiments. (E) BID pSAHB-1 was incubated with FL-BAK 
liposomes and the mixture subjected to UV irradiation, solubilization, electrophoresis, excision 
of the crosslinked protein, trypsin proteolysis, and LC-MS/MS analysis. The plots depict the 
frequency of crosslinked sites identified across the FL-BAK polypeptide sequence (left), with 
crosslinked residues mapped onto a calculated model structure of FL-BAK (based on sequence 
homology to BAX) and colored according to the frequency of occurrence (right). As no 
crosslinks to residues of the C-terminal helix of FL-BAK were observed, α9 was removed from 
the structure to better visualize the crosslinked residues at the surface of the canonical BH3-
binding pocket. Of note, residues of this same region were crosslinked by BID pSAHB-1 upon 
incubation with FL-BAK in solution (Fig. 4.2, A). 
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Next, we subjected recombinant full-length BAX to BID pSAHB crosslinking analysis to 
determine if pSAHBs were capable of detecting the α1/α6 trigger site.  Indeed, we find that BID 
pSAHBs crosslinked to a series of residues located within the previously defined BH3 trigger 
site at the N-terminal face of BAX (Fig. 4.5, A and B). Interestingly, BID pSAHB-2 also 
crosslinked to discrete residues within the canonical BH3 binding pocket of BAX (Fig. 4.5, B), 
suggesting that once triggered at the α1/α6 site, which was previously defined by biochemical 
and NMR studies as the initiating interaction for BAX activation9, compatible BH3 binding at 
the canonical groove upon allosteric release of BAX α9 can also occur.  
 
Another BH3-only activator helix, BIM pSAHB, detects differential binding and trigger 
sites for BAK and BAX 
To document that this paradigm holds for another activator BH3 helix, we generated and 
applied a BIM pSAHB in crosslinking analyses of both full-length BAK and BAX.  Again, we 
found that BIM pSAHB crosslinked exclusively to residues of the canonical BH3-binding pocket 
on BAK (Fig. 4.5, C), whereas a series of α1, α1-α2 loop, and α6 residues are also crosslinked 
only in BAX (Fig. 4.5, D). 
 
Self-propagating interactions of BAK/BAX BH3 SAHBs are analogous to those of BID 
and BIM and localize to differential binding pockets on BAK and BAX proteins 
Finally, to explore whether the distinct trigger sites for initiating direct activation of 
BAK/BAX by BID/BIM BH3 helices are also invoked during the self-propagation and/or 
oligomeric self-association steps of BAK/BAX activation9,18,19, we generated BAK and BAX 
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Figure 4.5. BID and BIM pSAHBs crosslink to the α1/α6 trigger site on BAX but not FL-
BAK. (A, B) In contrast to the results obtained with FL-BAK (Fig. 4.2), BID pSAHBs  
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Figure 4.5 (Contunued). 
 
crosslinked to a series of BAX surface residues located within the previously defined BH3 
trigger site formed by the confluence of α-helices 1 and 6 at the N-terminal face of BAX. BID 
pSAHB-2 crosslinked to two additional amino acids of the canonical BH3-binding pocket of 
BAX. The plots depict the frequency of crosslinked sites identified across the BAX polypeptide 
sequence, with crosslinked residues mapped onto the solution structure of BAX and colored 
according to the frequency of occurrence for each pSAHB (1, red; 2, green).  As BID pSAHB-
crosslinks to BAX α9 were not evident, the C-terminal helix was removed from the BAX 
structure to better visualize the crosslinked residues at the surface of the canonical BH3-binding 
pocket. (C, D) To compare sites of interaction for another direct activator BH3 helix with distinct 
sequence composition from BID BH3, a BIM pSAHB was employed in crosslinking analysis 
with FL-BAK and BAX.  BIM pSAHB exclusively crosslinked to residues at the C-terminal face 
of FL-BAK, including amino acids of the canonical BH3-binding pocket and α9 helix, as 
observed for the corresponding BID pSAHB with an N-terminally located benzophenone moiety 
(Fig. 4.2, C).  In contrast, the identical BIM pSAHB construct engaged a host of BAX surface 
residues at the α1/α6 trigger site on BAX in addition to select residues of the canonical groove.  
The plots depict the frequency of crosslinked sites identified across the FL-BAK and BAX 
polypeptide sequences, with crosslinked residues mapped onto the FL-BAK (grey) and BAX 
(blue) structures and colored according to the frequency of occurrence.  As BIM pSAHB-
crosslinks to BAX α9 were not evident, the C-terminal helix was removed from the BAX 
structure to better visualize the crosslinked residues at the surface of the canonical BH3-binding 
pocket. 
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pSAHBs for crosslinking analyses.  Consistent with the results observed for BID and BIM 
pSAHBs, BAK and BAX pSAHBs exclusively crosslinked to residues of the canonical BH3-
binding pocket of FL-BAK (Fig. 4.6, A and B), whereas the same pSAHBs either additionally or 
exclusively crosslinked to residues of the α1/α6 trigger site on BAX (Fig. 4.6, C and D).  
Whether or not the identified BAK BH3 in groove interaction reflects a propagation mechanism 
defined by nucleation of dimers that then oligomerize through a second stable binding interface 
as previously proposed20,21, or a linear auto-activation mechanism that ultimately produces a 
membrane-embedded oligomer of conformationally-altered monomers, remains to be structurally 
determined.  If the former case, the identified crosslinks between BAK SAHB and the canonical 
pocket of FL-BAK could likewise reflect a stable component of the homo-dimer or homo-
oligomer of BAK. Taken together, these data suggest that the initiating step for direct BAK and 
BAX activation, whether triggered by activator BH3-only domains or propelled by BAK/BAX 
BH3 domains, employs distinct BH3-binding interfaces on the two pro-apoptotic multidomain 
proteins – the canonical groove for full-length BAK and the non-canonical α1/α6 site for full-
length BAX. 
 
Summary 
To define the mechanism of direct BAK activation and the binding modes of activating 
BH3 domains, we employed a affinity labeling and mass spectrometry approach. We synthesized 
photoreactive SAHBs (pSAHBs) corresponding to the BH3 domains of BH3-only proteins BID 
and BIM, and to the BH3 domains of BAK and BAX, which have been hypothesized to 
participate in BAK and BAX auto-propagation.  Using our novel pSAHBs and full-length BAK 
and BAX constructs, we defined the differential BH3 binding modes of BAK and BAX proteins.  
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Figure 4.6. The BAK/BAX BH3 helices likewise engage distinct trigger surfaces on FL-
BAK and BAX. (A, B) BAK and BAX pSAHBs were incubated individually with FL-BAK and  
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Figure 4.6 (Continued). 
 
the mixtures subjected to UV irradiation, electrophoresis, excision of the crosslinked protein, 
trypsin proteolysis, and LC-MS/MS analysis. The plots depict the frequency of crosslinked sites 
identified across the FL-BAK polypeptide sequence, with crosslinked residues mapped onto the 
calculated model structure of FL-BAK structure (grey) and colored according to the frequency of 
occurrence. As BAK pSAHB-crosslinks to FL-BAK α9 were not identified, the C-terminal helix 
was removed from the calculated FL-BAK structure to better visualize the crosslinked residues 
at the surface of the canonical BH3-binding pocket. (C, D) When exposed to full-length BAX, 
the identical BAK and BAX pSAHBs crosslinked to a series of residues at the α1/α6 trigger site, 
with no canonical site crosslinks observed for BAK pSAHB and a select few identified for BAX 
pSAHB. The plots depict the frequency of crosslinked sites identified across the BAX 
polypeptide sequence, with crosslinked residues mapped onto the structure of BAX (blue) and 
colored according to the frequency of occurrence. As pSAHB crosslinks to BAX α9 were not 
evident, the C-terminal helix was removed from the BAX structure to better visualize the BAX 
pSAHB-crosslinked residues at the surface of the canonical BH3-binding pocket. 
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All of the above SAHBs bind BAK exclusively at the C-terminal canonical pocket (also found in 
antiapoptotic proteins), whereas the initial activation step of BAX is mediated by BH3 
engagement of an N-terminal trigger site.  
 
Methods 
Photoreactive SAHB Synthesis and Characterization 
Photoreactive SAHBs (pSAHBs) were generated as described15 by incorporating Fmoc-L-p-
benzoyphenylalanine (EMD Biosciences) at the indicated locations in the peptide sequence. 
 
Photoaffinity labeling 
pSAHBs were mixed with FL-BAK or BAX at a 1:1 ratio (10 mM) in Buffer A (20 mM 
Tris, 250 mM NaCl, pH 7.6), incubated for 10 min, and then irradiated at 365 nm for 2 hr on ice, 
in accordance with our previously reported method15. Unreacted pSAHBs were removed by 
dialyzing overnight at 4°C in Buffer B (200 mM NaCl, 50 mM Tris, pH 7.4) using 6-8 MWCO 
D-tube dialyzers (EMD Biosciences). Biotin capture was accomplished by incubating the 
reaction mixture with high-capacity streptavidin agarose (Thermo) in Buffer B. Streptavidin 
beads were washed with 1% SDS in PBS (3x), 1 M NaCl in PBS (3x), and then 10% ethanol in 
PBS (3x). Biotinylated proteins were eluted by boiling in 10% SDS solution (Promega) 
containing 10 mg/ml D-biotin, subjected to SDS-PAGE, and then visualized by Coomassie 
staining (Simply Blue Safestain, Invitrogen). Bands corresponding to crosslinked species were 
excised, subjected to in-gel digestion with trypsin, and then analyzed by LC-MS/MS (see below).  
 
Mass spectrometry analysis 
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Mass spectrometry analysis of covalent pSAHB interaction sites was performed as 
previously described15. Excised gel bands were destained, washed by dehydration, reduced with 
20 mM DTT in 100 mM ammonium bicarbonate, washed again, and then alkylated by incubation 
with 10 mM iodoacetamide in the dark. After washing and dehydration with acetonitrile, gel 
slices were rehydrated overnight in trypsin digestion buffer (12.5 ng/ml sequencing grade 
modified trypsin [Promega] in 50 mM ammonium bicarbonate). Following digestion, samples 
were extracted from the gel with 50% acetonitrile/5% formic acid in water, the solvent 
evaporated by speedvac, and the samples resuspended in 0.5% trifluoroacetic acid in 1M urea 
followed by desalting using C18 STAGE tips22. Samples were then subjected to nano LC-
MS/MS using a 20 cm column composed of a 100 mm i.d. fused silica capillary that was flame 
pulled in-house to produce an approximately 5 mm tip, and packed with Maccel C18 Resin (3m, 
200Å, The Nest Group, Inc.).  Data was collected on an LTQ Orbitrap Discovery hybrid mass 
spectrometer (ThermoFisher) operated in data-dependent mode15. The MS/MS spectra were 
assigned by searching with the SEQUEST algorithm23 against a sequence-reversed database 
containing BAK, the corresponding mutated BAK sequences, BAX, BCLXLΔC, trypsin, and 
common keratin contaminants.  Peptide false detection rates (FDR) were limited to <5% by 
filtering peptide spectral matches according to their XCorr, mass accuracy, tryptic state, charge 
state, and peptide length.  When filtering for crosslinked species, spectral matches corresponding 
to multiply crosslinked peptides or crosslinked keratins were considered contaminants and 
included in the FDR 5% limit.  The resultant list of high confidence sites of covalent 
modification were plotted by frequency of occurrence across the polypeptide sequence. 
 
Generation and characterization of FL-BAK liposomes 
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ANTS/DPX-loaded liposomes were generated as described in the liposomal assay 
method, except that FL-BAK (20 µM) was also added to the lipid film (1 mg) mixture in 200 
mM KCl, 1 mM MgCl2, 10 mM HEPES, pH 7.0. After extrusion (Avanti extruder) through a 100 
nm nucleopore membrane, FL-BAK-containing liposomes were purified by gravity-flow SEC, 
removing any non-incorporated FL-BAK from the preparation. Proteinase K digestion was 
performed at room temperature for the indicated durations. tBID treatment and Triton X-100 
lysis were performed as described in the liposomal assay method.  
 
Photoaffinity labeling and mass spectrometry analysis of membrane-embedded FL-BAK 
Site identification analysis using BID pSAHB-1 was performed as described for FL-BAK 
in solution except that (1) FL-BAK liposomes were used instead and (2) after UV irradiation, the 
mixture was incubated with 1% CHAPS to solubilize the FL-BAK liposomes prior to the 
overnight dialysis step that removes unreacted pSAHB. 
 
Contributions 
Elizaveta S. Leshchiner, Craig R. Braun, Gregory H. Bird and Loren D. Walensky 
contributed to this part of the work. E.S.L. expressed and purified recombinant proteins, 
conducted crosslinking experiments and analyzed data. C.R.B. conducted mass spectrometry 
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Discussion 
The oligomerization of BAK and BAX in the mitochondrial outer membrane is one of the 
ultimate control points for mitochondrial apoptosis1. As such, the mechanisms that underlie 
BAK/BAX regulation and channel formation remain a high-priority research focus of the cell 
death field. The production of recombinant BCL-2 family proteins has been an essential step for 
both dissection of their biochemical functions and for translation of these insights into potential 
therapies to modulate cell death in human disease. For example, bacterial expression and 
purification of anti-apoptotic BCL-XL, with the C-terminus removed and an unstructured loop 
trimmed, led to a fundamental understanding of how BCL-2 survival proteins trap the BH3 
helices of pro-apoptotic proteins to block cell death2,3 and provided a blueprint for the 
development of ABT-263, the first selective BCL-2/BCL-XL inhibitor to advance to clinical 
testing in cancer4-6.  Owing to the membrane-based activity of many BCL-2 family members, 
which is facilitated by a hydrophobic infrastructure including a C-terminal membrane insertion 
helix, the production of sufficient soluble, full-length, and monomeric recombinant protein for 
biochemical and structural analyses has been a longstanding challenge.  Given the importance of 
the C-termini of BCL-2 family proteins in protein structural integrity, membrane trafficking, and 
functional insertion into a membrane7-10, analysis of full-length constructs is highly preferred. 
For example, our understanding of the functional dynamics of BCL-w and BAX has been greatly 
advanced by the structural and biochemical analysis of the corresponding full-length proteins8,10-
13. Whereas the cytosolic disposition of select multidomain BCL-2 family proteins has favored 
bacterial expression and purification of full-length monomeric protein, expression of membrane-
localized members have been especially refractory.  
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To overcome the longstanding challenge of producing full-length, monomeric BAK, we 
undertook a surface mutagenesis approach to minimally hydrophilize its hydrophobic C-
terminus. In doing so, we developed the first full-length BAK construct amenable to bacterial 
expression, affinity chromatography, and FPLC-based purification in monomeric form14. 
Interrogation of this recombinant FL-BAK has led to a number of novel insights. First, in 
contrast to full-length recombinant BAX, soluble FL-BAK auto-translocates to isolated 
mitochondria, demonstrating a differential membrane tropism that is consistent with the relative 
subcellular distributions of BAX and BAK in vivo. Potential differences in affinity of the BAX 
and BAK C-terminal α9 helices for their respective binding pockets, leading to distinct 
propensities to release α9 for membrane insertion, could account for this phenomenon. Second, 
translocation of FL-BAK, in and of itself, does not permeabilize the mitochondria, indicating that 
a definitive activation step is required either in the form of a direct trigger or inhibition of 
suppressive heterotypic protein interactions. Third, the combined use of FL-BAK and BID 
SAHB enabled the quantitation of a direct and sequence-dependent interaction between BAK 
and an activator BH3 helix. The BH3-only protein tBID or its essential BH3 helix in the form of 
BID SAHB, activates and functionally oligomerizes FL-BAK in the absence of any other factors, 
definitively validating a direct activation mechanism for BAK.  Fourth, biochemical occlusion of 
the canonical BH3-binding pocket by disulfide tethering of the BAK C-terminal helix, abrogates 
the binding interaction between BID SAHB and FL-BAK, suggesting that, in contrast to BAX, 
the primary site for initiating direct BAK activation lies at the C-terminal face of the protein. 
Finally, with full-length BAK and BAX in hand, combined with the application of photoreactive 
SAHBs, we were able to perform the first comparative structural mapping of BH3 binding sites 
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on these essential executioner proteins, revealing distinct trigger sites for initiating and 
propelling their activation. 
Installation of photoreactive benzophenone moieties along the sequence of BH3 peptide 
helices enables an unbiased analysis of covalent intercalation sites on a target protein using 
proteomic methods15. The capacity to rapidly and accurately map binding interfaces with this 
combined chemical biology and MS/MS strategy provides an alternative and complementary 
approach to bridging the often multi-year gap until such interfaces are characterized by definitive 
structural methods such as NMR or X-ray crystallography. In this case, the application of BH3-
only direct activator helices8,16-18 (BID, BIM, BAK and BAX pSAHBs) all pointed to an 
exclusive site of direct FL-BAK interaction at its canonical binding groove. In striking contrast, 
the same pSAHBs consistently crosslinked to a distinct BH3-binding site localized to the 
opposite side of the full-length BAX protein, previously characterized by a battery of NMR and 
biochemical analyses as the trigger site for direct BAX activation16. Thus, to initiate BAK and 
BAX activation, membrane-localized BAK and cytosolic BAX employ distinct triggering 
surfaces. Interestingly, a subset of activator pSAHBs showed dual crosslinking to both the N-
terminal trigger (α1/α6) and C-terminal canonical BH3-binding sites on BAX, suggesting that 
once triggered at the N-terminus, release of the BAX C-terminus exposes a second BH3-
compatible binding interface at the canonical groove. Indeed, this concept of sequential BH3-
only binding interactions to drive BAX activation is supported by a prior stepwise analysis of 
tBID-induced BAX oligomerization19. Taken together, our data suggest that activator BH3-
engagement at the canonical pocket in the context of the mitochondrial outer membrane may 
represent a common mechanism for maintaining BAK and BAX in an activation-competent 
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state, with the α1/α6 triggering mechanism of BAX representing a unique afferent step required 
to regulate the activation and mitochondrial translocation of cytosolic BAX (Figure 5.1).  
 
Future directions 
BAX/BAK oligomeric pore structure 
The functional endpoint of BAK and BAX activation is membrane integration in the form 
of oligomeric pores, critical structures that remain to be defined. Indeed, the development of full-
length forms of BCL-2 family members, such as BAK, is an essential step to advancing our 
structural and biochemical understanding of the protein interaction dynamics that dictate their 
pro-apoptotic function in the membrane environment.  
The final structure of the apoptotic pore in the outer mitochondrial membrane has been 
elusive due to notorious difficulties associated with production, purification and structural 
characterization of BCL-2 family proteins. Intrinsic properties allow these proteins to (1) either 
exist in the membrane environment (BAK) or shuttle between cytoplasm and the mitochondrial 
membrane (BAX), perhaps reversibly20; (2) undergo dramatic conformational changes that 
involve the exposure of the protein hydrophobic core ; and (3) self-propagate and oligomerize. 
Importantly, the oligomeric pore of BAX/BAK has been reported to continuously propagate in 
size, resembling a chain reaction with more and more molecules of BAX recruited to the pore, 
making it challenging to isolate a single species of BAX/BAK oligomer21. Lipids are also an 
important part of the pore; proteinaceous, toroidal lipidic pores have been attributed to 
BAX/BAK oligomers, as opposed to clearly defined protein channels22. All of these technical 
challenges have prevented definitive structural determination of the BAX/BAK pore, which 
remains a high priority goal for the field.  
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Figure 5.1. Differential BH3 binding modes initiate the direct activation of full-length BAK 
and BAX. We interrogated the initiation site for BH3-mediated direct activation of BAK and 
BAX by employing a series of photoreactive activator BH3 helices. The BID, BIM, BAK and 
BAX BH3 helices engaged the α1/α6 trigger site on BAX but only the canonical BH3-binding 
pocket on BAK. Thus, activation of the full-length forms of both BAK and BAX are initiated by 
direct BH3 interaction, but at distinct trigger sites. 
 
	   116	  
Dewson et al. undertook an extensive mutagenesis approach to study BAK 
oligomerization in cells23. Their study revealed that, during apoptosis, BH3 domains of BAK 
become temporarily exposed and then reburied in dimers or oligomers, which was detected by a 
conformation-specific anti-BH3 antibody. Chemical crosslinking by small molecule agents that 
oxidize cysteines to disulfides (e.g. CuPhe) were most efficient when cysteines were installed in 
the BH3 domain and hydrophobic pocket of BAK, suggesting a direct interface of interaction at 
some stage of BAK oligomerization. Additionally, a designed BH3 mutation in BAK BH3 
rescued, albeit partially, a loss-of-function hydrophobic groove mutant of BAK.  
Analogous studies on the opposite side of BAK, close to its N-terminus, revealed that 
BH3:groove dimers can oligomerize by forming a second interface at the α6 surface of 
neighboring BAK molecules24. Cysteine residues introduced in α6 could be crosslinked upon 
apoptotic stimulation once the BH3:groove dimer was formed, leading to the conclusion that 
BAK oligomers are composed of symmetrical BAK dimers, as schematically depicted in Figure 
5.2, A. Furthermore, at least 18 BAK molecules are required to compose an oligomeric pore, 
althoughthe definitive size of the physiologic BAK oligomeric pore has not been defined. This 
induced cysteine crosslinking approach provided an explaination for how  N-terminal α1/α6 
exposure of BAK during apoptosis could contribute to BAK oligomerization. However, how the 
pore lumen is formed was not resolved. If the toroidal pore model is correct, then at least some 
parts of the BAK protein must be submerged in the lipidic bilayer, completely distorting the 
inactive BAK structure. Thus, the oligomer of dimers model may be a transient state during 
BAK oligomerization. Analogously, BAX was proposed to form a similar dimeric structure upon 
activation. Two BAX molecules inserting their BH3 domain into each other’s canonical binding 
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Figure 5.2. Alternative models for proapoptotic BAK and BAX oligomeric structures. (A) 
The “oligomer of dimers” model postulates that BH3:groove dimers are the fundamental unit of 
oligomeric pore formation. (B) Oligomeric chains of single conformers may alternatively 
comprise the pore structure of BAK and BAX. (C) Dramatic conformational changes accompany 
BAK and BAX oligomerization, including exposure of the BAK and BAX hydrophobic core and 
permeabilization of the lipidic bilayer. 
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groove form a symmetric dimer, which was proposed to also nucleate formation of the 
oligomeric pore25,26. 
An alternative view for BAK oligomerization was proposed by Pang et al27. By using 
molecular dynamics simulations, BAK was proposed to form asymmetric single-conformer 
oligomeric chains (Figure 5.2, B), as opposed to the “oligomer of dimers” model. Other 
observations may suggest yet another mechanism. All of the above models assume that the 
structure of BAX/BAK molecules in the final oligomeric pores is similar to the initial 
monomeric structures. However, these proteins possess a highly hydrophobic core, which may 
become exposed to the membrane environment during BAX/BAK conformational changes. This 
would promote a very dramatic conformational change in the monomeric unit structure in the 
pore as compared to the initial structure of BAK/BAX, consistent with protein unfolding in the 
membrane environment (Figure 5.2, C)28.  
New insights continue to emerge from strutcural analyses of BAX and BAK. In 2013, the 
first crystal structure representing a dimeric form of BAX was reported26. Even though severely 
truncated (only helices α2-α5 were included, which represents less than half of the protein 
sequence), the structural data suggestthat the canonical pocket interaction may be important in 
BAX dimerization and potentially oligomerization.  
With full-length BAX and now BAK in hand, we are poised to generate more definitive 
structural data on BAK and BAX, and how they self-associate to form pores.  
 
Development of new pharmacologic agents targeting pro-apoptotic BCL-2 family 
members 
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Cancer cells often hijack the apoptosis pathway mediated by the BCL-2 family of 
proteins by pathologically overexpressing antiapoptotic proteins. The structures of antiapoptotic 
BCL-2 family proteins and their complexes with BH3 peptides stimulated major efforts to 
develop inhibitors of antiapoptotic proteins capable of restoring cell sensitivity to apoptotic 
stimuli. Several small molecules4-6 and stapled peptides29,30 have since been developed that 
indirectly activate the mitochondrial apoptosis by binding to and inhibiting the hydrophobic 
binding groove of antiapoptotic proteins, reducing the antiapoptotic blockade. Some of these 
compounds are already being tested in clinical trials as promising next-generation cancer 
therapeutics6. 
Recently, a novel approach was undertaken to develop small molecule BAX activators. 
These novel pharmacologic agents employ a different strategy: instead of stimulating apoptosis 
indirectly via inhibition of antiapoptotic proteins, BAX activators directly bind to and activate 
BAX31. Our characterization of the differential trigger sites for BAK and BAX14 allows for 
extension of the development of selective pharmacologic agents for BAK activation. 
Whereas BAX/BAK activation promotes apoptosis, inhibition of BAX/BAK 
oligomerization and mitochondrial poration would potentially lead to inhibition of apoptosis and 
could hypothetically be used in diseases of acute cell death. Importantly, several findings have 
provided evidence that other forms of cell death, including necrosis, are also dependent on BAK 
and BAX32,33. This suggests that acute inhibition of BAX/BAK may be beneficial as a 
therapeutic strategy to prevent tissue loss at the earliest stages of myocardial infarction or stroke. 
Several BAX channel inhibitors have also been described34.  The therapeutic potential of this 
entirely new class of agents, directed at activating or inhibiting BAX/BAK, represents an 
exciting drug development frontier.   
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Dissecting the BCL-2 family interactome 
In addition to the essential roles of BCL-2 family proteins in regulating apoptosis, non-
canonical functions have also been described.  For example, unanticipated roles for BCL-2 
family members (and  BH3-only proteins in particular) in autophagy35, the DNA damage 
response36,37, glucose homeostasis38,39, cell cycle progression40 and calcium signaling have been 
reported41,42. 
With new chemical biology and proteomic tools in hand, we aim to advance a systematic 
study of the BCL-2 family interactome. Proteomic approaches such as immunoprecipitation of a 
tagged protein bait followed by mass spectrometry-based identification of bound targets has been 
widely used to search for novel protein interactions, and could be applied to BCL-2 family 
proteins. However, a major impediment to performing such screens in high-throughput fashion is 
the necessity to validate large sets of hits individually. Correct mass spectrometry identification 
of the protein target, confirmation of direct binding, and uncovering the functional consequences 
of interaction, represent a complex and time-consuming workflow. We propose to use stabilized 
peptides (SAHBs) corresponding to the BH3 domains of the BCL-2 family proteins as the first-
pass validation screen, after an initial set of binding partners has been identified by direct protein 
immunoprecipitation. The benefits of using stapled peptides are four-fold. First, the native shape 
of the BH3 domain is preserved, maintaining a physiologically relevant bait. Second, SAHBs can 
be modified to include a biotin tag (for straptavidin pull-down), which provides an orthogonal 
means of identifying high-confidence targets, as non-specific binding to antibody-containing 
beads and streptavidin beads should not fully overlap. By filtering against non-specific binders 
under harsh conditions in both experimental setups, confident in the derived hits would be 
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increased. Third, use of photoreactive SAHBs, or pSAHBs, allows for covalent capture of the 
binding partners from cellular lysates upon UV irradiation, enabling detection of direct 
interaction partners in a high-throughput manner. Finally, an additional benefit of using pSAHBs 
is the structural determination of the binding site that can follow immediately after binding 
partner identification, provided that at least some structural information is available on 
theidentified ‘hit’ protein. The ability to quickly determine any structural information for the 
newly proposed interaction is crucial to validating the binding mechanism, designing 
expeirments to probe the functional consequences, and advancing pharmacologic approaches for 
targeting the protein interaction for potential therapeutic benefit.  Piloting the approach BAK 
protein and BAK BH3 SAHBs, I can accurately detect known BAK interactors. For example, 
BCL-2 family interactors such as MCL-1 were detected in BAK SAHB immunoprecipitations 
but not in vehicle controls. These data highlight the promise of the proposed multi-step approach, 
with sequential verification of the obtained hits under stringent conditions. 
By extensively studying tBID-mediated BAK and BAX activation in the course of this 
thesis work, I became increasingly interested in some of the unique properties of the BID 
protein. Structurally, BID more closely resembles the structure of multidomain than BH3-only 
proapoptotic proteins. In particular, BID contains the classical fold of multidomain BCL-2 
family members: two hydrophobic helices at the core (α5 and α6) surrounded by several 
amphipathic helices43.  In contrast, the majority of BH3-only proteins are unstructured, with the 
exception of their BH3 domain α-helices, some of which take shape only when bound to their 
protein targets. Interestingly, BID has been implicated in cellular processes other than apoptosis. 
For example, BID is believed to participate in the DNA damage response36,37 (although 
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conflicting reports exist44) and also serves as a component of the inflammasome complex45, 
potentiating innate immune signaling.  
I observed that Bid-/- mouse embryonic fibrosblasts (MEFs) grow significantly more 
slowly when compared to wild-type MEFs (data not shown), suggesting a potential role for BID 
in cellular processes other than apoptosis. I set out to perform proteomics-based identification of 
BID binding targets using the methodology described above. Because overexpressing BID is 
cytotoxic, we instead conjugated recombinant BID protein to biotin. By measuring optical 
absorbance spectra, I quantified the number of biotin molecules attached to each BID protein 
molecule, and the yield was approximately 2 biotin moieties per molecule of BID protein. I 
incubated the biotinylated BID protein with streptavidin beads to generate BID-coated beads, 
which were then used to perform affinity capture from cellular lysates. After mass spectrometry-
based identification of protein targets, a similar procedure was performed for BID SAHB, and 
the lists of hits were compared.  
Importantly, I detected BID protein and BID SAHB interactions with select BCL-2 
family proteins (e.g., BAX, BAK, MCL-1), as well as non-canonical interaction partners that 
have been described previously (e.g., ATM, ATR). Additionally, I detected several novel, 
unexpected targets, which I am currently validating experimentally. BID could potentially 
regulate or be regulated by46 some of the identified protein targets. We further plan to extend the 
studies of BAK and BID interaction partners to include photoreactive crosslinker (pSAHBs) 
analyses. In a sequential validation step, I will perform reverse immunoprecipitations to validate 
the presence and abundance of the candidate protein interaction. I will create a cumulative 
confidence score based on the number of peptides detected in the mass spectrometry 
experiments, normalized to the molecular mass of the corresponding protein hit and to its 
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abundance in the cellular proteome (e.g. http://pax-db.org/#!home). Biological validation of novel 
protein interactions remains a critical step of this type of BCL-2 family interactome analysis.  
 
Non-canonical pathways for direct BAX/BAK activation 
Several studies have suggested the involvement of non-canonical regulation of 
mitochondrial apoptosis. One striking example involves the p53 protein, which inducescell cycle 
arrest and transcriptional upregulation of key apoptotic genes in response to discrete stimuli, 
such as DNA damage. A direct role for p53 in outer mitochondrial membrane permeabilization 
has also been described, involving BAX- 47 and BAK-dependent48 mechanisms49. Thus, tumor 
suppressor pathways may engage the BAX/BAK machinery directly.   
Studies undertaken by Keren Hilgendorf and Jacqueline Lees at MIT investigated a role 
for the retinoblastoma protein (pRB) in activating mitochondrial apoptosis. pRB has previously 
been detected outside of the nucleus, in both the cytoplasm50,51 and mitochondria52, although the 
function of pRB at these sites is unknown.  Lees and colleagues observed that inducible 
expression of pRB in MEFs significantly increased TNF-α-induced apoptosis (personal 
communication). This apoptosis enhancement was only observed in wild-type and Bak-/- pRB-
expressing MEFs, but not in Bax-/- or Bak-/-Bax-/- (DKO) MEFs, suggesting a role for BAX in this 
process. 
To explore a functional connection between BAX and pRB, we isolated liver 
mitochondria from Alb-cre posBax f/-Bak-/- mice. When incubated with recombinant BAX protein, 
pRB induced cytochrome c release, as documented by western blotting for cytochrome c in the 
supernatant and pellet (mitochondrial) fractions (Figure 5.3, A). This mitochondrial 
permeabilization was both dose-dependent and BAX-dependent. 
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Figure 5.3. pRB induces mitochondrial and liposomal permeabilization by directly 
activating BAX. 
(A) Bax-/-Bak-/- mouse liver mitochondria were isolated, and supplemented with the indicated 
amounts of recombinant BAX and recombinant human pRB. Cytochrome c release was assessed 
after incubation and centrifugation by western blotting of the pellet and supernatant fractions. 
pRB dose-dependently promoted BAX-mediated cytochrome c release from mitochondria (B) 
ANTS/DPX-loaded liposomes were incubated with the indicated concentrations of recombinant 
pRB in the presence or absence of recombinant BAX. pRB yielded dose-dependent BAX-
mediated liposomal permeabilization. (C) In vitro BAX activation as monitored by 6A7 epitope  
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Figure 5.3 (Continued). 
 
exposure of activated BAX. Immunoprecipitations were performed by using the 6A7 
conformation-specific BAX antibody. (D) pRB was co-precipitated with activated BAX as 
assessed by the 6A7 immunoprecipitation assay. (A-D) Data are representative of at least three 
independent experiments. 
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I then tested pRB-induced BAX activation in a liposomal context that lacks potentially 
confounding mitochondrial factors. I generated ANTS (fluorescent dye)/DPX (quencher)-loaded 
liposomes and monitored their permeabilization fluorometrically. Consistent with the 
cytochrome c release experiments, pRB induced BAX-dependent pore formation and release of 
the fluorescent dye (Figure 5.3, B). Neither BAX nor pRB alone at concentrations up to 250 nM 
were capable of permeabilizing the liposomes. 
Upon activation, BAX undergoes a conformational change, which allows the use of a 
conformation-specific antibody (6A7) to immunoprecipitate activated BAX. I performed an in 
vitro binding experiment in which pRB was incubated with recominbant BAX protein, and BAX 
activation was monitored by 6A7 immunoprecipitation followed by western blot analysis (Figure 
5.3, C). These results clearly demonstrated that pRB promoted BAX activation and its associated 
conformational change. I also confirmed the direct interaction between pRB and BAX in the 
context of BAX activation. Using the same 6A7 immunoprecipitation conditions to isolate 
activated BAX species, I documented that pRB protein co-immunoprecipitated with recombinant 
BAX in vitro (Figure 5.3, D). Thus, pRB can associate with BAX and triggers its conformational 
activation, which leads to membrane permeabilization. These results suggest that alternate 
paradigms for direct BAX and BAK activation may exist, and participate in the regulation of 
mitochondrial apoptosis.  
By appyling our interactome analyses, as described above, we aim to systematically 
examine the BCL-2 family interactome and how non-canonical interaction partners may 
contribute to regulating key signaling pathways during health and disease.  
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